INDEX TO VOLUME 50—1982

INDEX TO AUTHORS

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

ABDULLAEV, A. H., (A) 534
ABE, M., (A) 257, 600
ABOU-ZEID, C., (A) 401
ABRAHAM, J. C., (A) 266
ADAM, C., (A) 394
ADAPOE, C., (A) 400
ADU, H. O., (A) 256
AFFRONTI, L. F., (A) 567
AGARWAL, S. K., (A) 392
AGIB, A. M., (A) 253
AKIYAMA, T., (A) 399, 595
ALBINI, B., (A) 550
ALBRITTON, W. L., (A) 406
ALLEN, B. W., (A) 255
ALVARADO, J., (O) 415
AMBROSE, E. J., (A) 555
AMERIO, N., (A) 402
ANAND, B. S., (O) 148, (A) 546
ANBALAGAN, M., (A) 564
ANDERSON, R., (A) 386, 539, 566
ANDRIANJATOVO, J., (A) 127
ANDRIANTSOA-RASOAVELONORO, V., (A) 127
ANTIA, N. H., (A) 401
APOLINAIRE PENNIN, J. J., (A) 260
ARANZAZU, N., (O) 415, (A) 550
ARENAS, R., (A) 129
ARNOLD, H. L., (A) 243
ARNOLD, J., (A) 393
ARPINI, R. H., (A) 389, 389
ASSELINEAU, C., (A) 131, 400
ATLAW, T., (A) 253
AZIZ, A., (A) 409
AZULAY, R. D., (C) 215, (N) 225

BACH, M.-A., (O) 282
BAHADUR, B., (A) 537
BAHR, G. M., (A) 129, 394
BAI, K. I., (A) 563
BAILY, P., (A) 128
BAJAJ, A. K., (O) 43, (C) 219, (O) 468
BAJI, P. S., (A) 540
BAKKE, A. C., (A) 596
BALAKRISHNAN, S., (A) 535, 560
BANERJEE, K., (C) 509
BANO, H., (A) 243
BAPAT, C. V., (A) 130
BARANOV, Y. N., (A) 246
BARAS, M., (A) 560
BARBAJOSE, P. G., (A) 561
BARKSDALE, L., (A) 400
BARRILE, A., (A) 390
BARTON, R. P. E., (O) 58
BAUER, M., (A) 130
BAUMANN, E., (A) 544, 545
BECHELLI, L. M., (N) 122, (O) 325, (A) 547, 548, 561
BECK, J. S., (A) 251
BEHERA, F., (A) 406
BEIGUELMAN, B., (E) 501
BELDA, W., (A) 257
BELEHU, A., (O) 1, (A) 253, (O) 291, (A) 397, (O) 455, (A) 547, 553, 553
BENKATESAN, K., (A) 535
BERGSVIK, H., (A) 397
BERNAL, D., (A) 264
BHARADWAJ, M. P., (A) 388, 393, 535, 540, 543, 554, 561, 600
BHARASWADKER, M. S., (O) 143
BHASKARAM, P., (A) 135
BHAT, R., (A) 557
BHATIA, V. N., (A) 535, 560
BHATKI, W. S., (A) 130
BHIDE, M. B., (A) 400
BHUTANI, L. K., (O) 297
BINFORD, C. H., (A) 267, 385, 584
BINKHUYSEN, F., (O) 76
BJUNE, G., (A) 258, (O) 425
BOMGAARS, M. R., (O) 335
BONINI, S., (C) 217
BOTTASSO, A., (A) 402
BOTTASSO, O., (A) 249
BOURLAND, J., (A) 245, 535
BOVAL, C., (A) 407
BRAND, P. W., (Ob) 359
BRANDENBURT, K., (O) 90
BRANDT, F., (A) 128, 128
BRENNAN, P. J., (A) 132, 534, 591, 592
BROOR, S. L., (A) 537
BROSTOFF, J., (A) 134
BROWN, H. L., (A) 584
BROWN, R. A., (A) 251
BROWNE, S. G., (N) 120, 121, (C) 221
BRUNTON, J. L., (A) 406
BRYCESON, A., (A) 258
BUCHANAN, T. M., (A) 547, 593
BULAKH, P. M., (O) 143, (A) 540, 541
BULLOCK, W. E., (A) 601

CABRINI, J. L., (A) 249
CABRINI, J. M., (A) 249, 389, 389
CAMARGO, E. E., (O) 200
CANTARELL, C., (A) 539
CANTWELL, A., JR., (A) 408
CAP, J. A., (A) 258
CAPRON, A., (A) 267
CARDAMA, J. E., (A) 388
CARDENAS, Z. L., (A) 541
CARMINATTI FREGNAN, R., (A) 547
CARO, L., (A) 264
CARRERA, M., (A) 539
CASAL, M., (A) 566
CASTRO-COTO, A., (A) 388, 390
CAUZZI, N., (A) 249
CHAKRAVARTI, R. N., (A) 246, 543, 555
CHAN PIN JIE, J. C., (A) 399
CHAPO, R., (A) 389, 389
CHAROSKY, C. B., (A) 267, 388
CHATTERJEE, B. R., (A) 400, 400
CHATTERJI, P., (A) 248
CHAUBE, C. P., (A) 408
CHAUBEY, B. S., (A) 389
CHAUDHARI, D. T., (A) 387, 387
CHAUDHARY, R. C., (A) 566
CHEDID, L., (A) 394
CHHABRA, B., (O) 43, (C) 219
CHON, J. Y., (A) 394
CHOVET, M., (A) 128
CHRISTIAN, M., (A) 259
CHULLAWALLA, R. G., (A) 130
CHUN, I. K., (A) 394
CLAVEL, S., (A) 131
CLEMENT, F., (A) 131
CLOSS, O., (A) 259, 397, (O) 455, (A) 547
COATES, A. R. M., (A) 255
COCITO, C., (A) 256, 401, 554
COLSTON, M. J., (A) 556, 557
COMERCI, N. N., (A) 388
COMPA, F. V., (A) 389, 389
CONSIGLI, C. A., (A) 385
CONVIT, J., (O) 415, (A) 550
COOK, G. C., (A) 541
CORN, J., (A) 394
CORONA, C., (A) 249
CORONA, C. J. J., (A) 249, 402
COTTENOT, F., (O) 282
COUDERT, J., (A) 554
COULAUD, J. P., (A) 394
CRAWFORD, C. L., (C) 367
CRAWSHAW, R., (A) 534
CURTIS, J., (A) 256

D'AMARO, J., (A) 405
DABHOLKAR, V. R., (A) 541
DAFFE, M., (A) 131, 400
DAFTARY, D. K., (A) 545
DAHA, M. R., (A) 399
DAMLE, P. B., (A) 126
DAMLE, P. S., (A) 401
DANHAIVE, P., (A) 256
DANIEL, A. A., (A) 541
DAS, P. K., (O) 76
DASH, R. J., (A) 543
DASTUR, D. K., (A) 249
DATE, A., (O) 56, (E) 351
DATTA, , B. N., (A) 543
DAUTH, J., (A) 566
DAVID, H., (A) 131
DAVIDSON, P. T., (A) 126
DAVLEKAMOVA, F. A., (A) 262
DAYAL, S. S., (A) 552
DE LA PANOUSE, A., (A) 128
DE LIMA FILHO, E. C., (A) 548
DE VRIES, R. R. P., (A) 260
DELVILLE, J., (A) 554
DEO, M. G., (A) 130
DESAI, S. R., (A) 542
DESHPANDE, V. A., (A) 541
DESIKAN, K. V., (A) 244, 388, 393, 395, 552, 553, 561, 594, 600
DHARMENDRA, (A) 250, 561
DHOLAM, S. B., (A) 400
DHOPLE, A. M., (O) 83, (A) 255
DIMITROVA, I., (A) 403
DINLE. Y. H., (A) 253
DOMINGUEZ, V. M., (A) 561
DONG LI-WEN, (A) 267, 541
DORRINGTON, L., (A) 385
DOUGLAS, J. T., (A) 600
DRAPER, P., (C) 220, (O) 436
DUBEY, G. K., (A) 389
DUDANI, I. U., (A) 566
DUDHALKAR, B., (A) 404
DUERKSEN, F., (A) 405
DUNCAM, M., (A) 128
DUNCAN, M. E., (O) 31, (A) 397, (O) 425
DUNG GU-JING, (O) 172
DUTTA, A. K., (A) 554
DUTTA, R. K., (A) 389
DUURSMA, J., (A) 251
DYRTING, A. E., (O) 47

EL HASSAN, A. M., (A) 268
ELLARD, G. A., (O) 58
EMERY, R., (A) 560
ESASHIKA, I., (A) 595
ESPANA, A., (A) 389
ESTRADA-PARRA, S., (O) 306

FABER, W. R., (A) 399
FAIRBANK, A., (A) 253
FANKULE, Y. M., (A) 390
FARB, H., (A) 243
FARNARIER, G., (A) 542
FARRELL, J. P., (A) 409
FEKETE, E., (A) 390
FENG, P. C. C., (A) 385, 536
FENG BI, (A) 251
FENSELAU, C. C., (A) 385, 536

Ferlazzo, B., (A) 390
Fine, P. E. M., (A) 260
Fiol, L. M. B., (A) 541
Fliess, E. L., (A) 394, 398, 542, 543
Fort, J., (A) 539
Fotedar, A., (A) 547
Freiberger, H. F., (A) 128
Friedman, S. M., (A) 562
Fudenberg, H. H., (A) 128
Fujita, S., (A) 248
Fujiwara, T., (A) 591
Fukunishi, Y., (O) 68, (A) 589, 589

Gailly, G., (A) 401
Gaitonde, B. B., (A) 541
Ganapati, R., (A) 404
Ganatra, R. D., (A) 567
Ganeriwal, S. K., (A) 540
Gangadharam, P. R., (A) 126
Ganguli, D. D., (A) 393
Ganguly, N. K., (A) 543, 555
Gangwar, D. N., (A) 537
Garbajosa, G., (O) 436
Garbellini, D., (A) 263
Garcia, R., (A) 542
Gardner, I. D., (A) 596
Gatner, E. M. S., (A) 134, 386, 539, 566, 566
Gatti, J. C., (A) 388
Gautam, K. D., (A) 408
Gelfand, M., (A) 546
Geniteau, M., (A) 394
Gerone, P. J., (A) 267, 584
Ghei, S. K., (A) 395
Ghosh, M., (A) 542
Ghosh, S., (A) 540
Gibbs, J. H., (A) 251
Gidoh, M., (A) 244, 386, 589, 590
Gillis, T. P., (A) 547, 593
Gimenez, M., (A) 395
Girdhar, A., (A) 535
Girdhar, B. K., (A) 393, (O) 477, (A) 540
Godal, T., (A) 397
Gonzalez, A. N., (A) 260
Gonzalez, J., (A) 544
Gonzalez, M., (A) 264
Gonzalez-Cruz, O., (O) 306
Goodfellow, M., (A) 267, 408
Gopinath, T., (A) 398
Gormus, B. J., (A) 584
Gorodetsky, R., (A) 247
Gregory, D., (A) 557
Greiner, J., (A) 130
Gridel, F., (A) 392
Grosset, J., (A) 407, 555
Grover, S., (A) 389
Gu Shenggui, (A) 251
Gu Zhijie, (A) 548
Guedes, M., (A) 550
Guelpa-Lauras, C. C., (A) 555
Guevara, J., (A) 264
Guha, P. K., (A) 542
Guimaraes Pagnano, P. M., (A) 547, 548
Guinto, R. S., (B) 239
Gupta, S. C., (O) 43, (C) 219 (O) 468
Gupta, S. K., (O) 297
Gyi, M. M., (A) 561

Haddad, N., (O) 325, (A) 547
Hah, Y. M., (C) 510
Hajra, S. K., (A) 540
Hanks, J. H., (A) 255
Haque, A., (A) 267
Harahap, M., (A) 267
Harboe, M., (O) 1, (A) 261, 261, (O) 271, 291, (E) 342, (A) 397, 397, 547
Hardas, U. D., (A) 536
Haregewoin, A., (O) 1, 291
Hargrave, J. C., (N) 232, 511
Harikrishnan, S., (A) 560
Hastings, R. C., (E) 102, (B) 383, 384, (N) 514, (A) 552, 579
Hee Chul Eun, (A) 549
Hejny, J., (A) 407
Henika, P. C., (A) 558
Hewitt, J., (A) 255
Hidalgo-Hidalgo, H., (A) 388, 390
Hilson, G. R. F., (A) 556
Hirata, T., (A) 577
Hirooka, Y., (A) 558
Hoet, P., (A) 256
Hofman, F. M., (C) 361, (A) 596
Hogerzeil, L. M., (A) 561
Hong Sik Kim, (A) 549
Horwitz, D. A., (A) 596
Howland, C., (A) 265
Hua, A., (A) 391
Hua Wenyuan, (A) 549
Huang Li, (O) 471
Hudiono, H., (A) 405
Hugelin, A., (A) 565
Huikeshoven, H., (A) 387
Humber, D. P., (C) 367
Humphres, R. C., (A) 558
Hunter, S. W., (A) 132, 591
Husser, J. A., (A) 393
Hutchinson, I. G., (A) 408

Ikeda, M., (A) 248
Ilias, M. I., (A) 405
Imaeda, T., (A) 400
Imkamp, F. M. J. H., (A) 386, 539
Irgens, L. M., (A) 261
Ishaque, M., (A) 132, 400, 555
Ishidate, M., (O) 480
Ishihara, S., (O) 480
Ito, T., (O) 480, (A) 582, 583
Ivanyi, J., (A) 255
Iyer, C. G. S., (A) 244, 553

Izumi, A. K., (A) 407
Izumi, S., (A) 562, 595

Jacobson, R. R., (A) 385, 536, 552
Jagannath, C., (A) 395, 396
Jain, R. K., (A) 563
Jain, V. K., (A) 393
Jalgaonkar, S. V., (A) 536
Janczura, E., (A) 401
Janssens, L., (A) 537
Jerath, V. P., (A) 542
Ji Baohung, (A) 537
Job, C. K., (O) 177, 488
Joglekar, V. K., (A) 389
Johnsen, D. O., (N) 375
Jones, R. R., (A) 127
Jordan, R. E., (A) 407
Jose, F. A., Jr., (Ob) 213
Juji, T., (A) 404
Juscenko, A. A., (A) 254, 257
Juwatkar, P. S., (O) 330

Kadival, G. V., (A) 567
Kale, R. N., (A) 567
Kanai, K., (A) 135
Kannan, K. B., (A) 543
Kano, K., (A) 550
Kanwar, A. J., (A) 393
Kapur, T. R., (A) 542
Karazawa, E. H., (A) 550
Kashiwabara, Y., (A) 588
Kasili, E. G., (A) 246
Kataria, Y. P., (A) 246
Kato, L., (C) 368, (A) 400
Katoch, K., (A) 543
Katoch, V. M., (A) 554
Kaur, S., (A) 246, 537, 538, 543, 543, 546, 555
Kawaguchi, Y., (A) 558
Kazda, J., (A) 262
Kelkar, S. S., (A) 247, 557
Kenzhebaev, A. Y., (A) 396
Kertcher, J. A., (O) 200
Keuchler, C., (A) 601
Khanolkar, S. R., (A) 401, 555
Kharatyan, A. M., (A) 396
Kher, J. R., (A) 540
Khuller, G. K., (O) 319, (A) 567, 567
Kidson, C., (A) 262
Kim, D., (A) 386, 396 (C) 510, (A) 549
Kim, Y., (A) 391, 397
Kim, Y. P., (A) 394
Kim, Y. S., (A) 394
Kirchheimer, W. F., (O) 177, (N) 226, (A) 396, 400, (O) 488
Kist, P., (A) 128
Kliemann, T. A. E., (A) 550
Kobayashi, S., (A) 404
Kober, H., (N) 513
Kogan, V. R., (A) 262
Kohsaka, K., (O) 68, 480, (A) 557, 578, 582, 583
Kolhatkar, M. K., (O) 143
Kolumban, S. L., (A) 406
Kondo, E., (A) 135
Kong Qingying, (O) 316, 471
Kono, S., (A) 248
Koranne, R. V., (A) 563
Koseki, Y., (O) 480, (A) 577
Koticha, K. K., (O) 330
Kouemeni, L. E., (A) 267
Kouri Flores, J. B., (A) 556
Kowale, C. N., (A) 541
Krahenbuhl, J. L., (A) 558
Kromann, N. P., (A) 537
Kronvall, G., (A) 263
Kukreja, N., (A) 268
Kulkarni, V. N., (A) 564
Kumamaru, S., (A) 248
Kumar, A., (A) 564
Kumar, B., (A) 246, (O) 319, (A) 537, 538, 543, 543, 546, 555
Kumar, K., (A) 406
Kumar, N., (O) 148
Kuratsune, M., (A) 248
Kvach, J., (O) 183
Kwapinski, J. B. G., (O) 325

Lagrange, P. H., (A) 131
Lahiri, S. C., (A) 252
Lai A Fat, R. F. M., (A) 399
Laing, A. B. G., (A) 244
Lancaster, R. D., (A) 556
Laneelle, M. A., (A) 131, 400
Langendijk, E. M. J., (A) 553
Languillon, J., (A) 394, 540
Larson, S. M., (O) 200
Latapi, F., (N) 516
Lechat, M. F., (N) 119, 122, (A) 263, (N) 511, 515, (B) 524
Lecoeur, H., (A) 555
Lee, H., (A) 397
Leena Devi, K. R., (A) 398
Lefford, M. J., (A) 133
Leiker, D. L., (A) 387
Leininger, J. R., (A) 267
Lemieux, S., (O) 494
Lenzini, L., (A) 134
Leon, A. P., (A) 130
Levis, W. R., (A) 562
Levy, L., (Ob) 508, (A) 559, 559, 560, 560
Lindner, B., (O) 90
Li Wenzhong, (A) 126
Liu Jihe, (O) 316, 471
Liu Tze-chun, (O) 172
Liu Zijun, (A) 550, 551
Llorente, B., (A) 542, 543
Loewinger, E., (A) 247
Logie, P. S., (A) 133
Lombardi, C. A., (A) 257
Londono, F., (A) 264
Loretti, A., (A) 263
Louvet, M., (A) 392
Løvik, M., (A) 397

Lu, H. T., (A) 554
Lutsky, I., (A) 559, 559
Lwin, K., (A) 561

Ma Bukuan, (A) 126
Ma Haide, (N) 225
Ma Lin, (A) 126, 251
MacDonald, E. M., (A) 560
Mackel, S. E., (A) 407
MacLean, I., (A) 406
Maeda, H., (A) 404
Magnusson, M., (A) 263
Mahadevan, P. R., (A) 555
Mahakrisnan, A., (A) 135
Mahamud, I. A., (A) 253
Maheswari, H. B., (A) 552
Malaviya, A. N. (A) 268
Malaviya, G. N., (A) 391, 543, 565
Malhotra, V., (O) 148
Malhotra, Y. K., (A) 393
Malik, A. K., (A) 537
Malik, R., (A) 546
Malik, U., (O) 319, (A) 567, 567
Malla, O. K., (A) 128
Manzi, R. O., (A) 564
Martin, L. N., (A) 584
Martinez, E. W., (A) 550
Mathai, R., (O) 56
Matsouka, M., (A) 558
Matsumoto, Y., (A) 562, 595
Matsunaga, J., (A) 407
Matsuo, E., (A) 599
Matsuo, Y., (A) 401, (O) 480, (C) 510, (A) 556, 578
Mauff, G., (A) 130
McDougall, A. C., (O) 58, (C) 214, (E) 355, (O) 477, (A) 540
McNulty, J. C., (A) 562
Meghlaoui, A., (A) 250
Mehra, N. K., (A) 405
Mehrotra, M. L., (A) 394, 408
Mehrotra, T. N., (O) 43, (C) 219, (O) 468
Mehta, J. M., (A) 564
Mehta, M. C., (O) 143
Melsom, R., (O) 271, (A) 397, 397, (O) 425
Meness, A., (A) 264
Merkus, F. W. H. M., (A) 387
Mester, L., (A) 535
Meyers, W. M., (A) 267, 385, 584
Michal, F., (B) 525
Middlebrook, G., (A) 409
Mikhailov, P., (A) 403
Milgrom, F., (A) 550
Miller, R. A., (A) 593
Mimica, I., (A) 550
Minagawa, F., (A) 257, 600
Minjat, M., (A) 554
Minnikin, D. E., (A) 267, 408
Minnikin, S. M., (A) 408
Mirza, Z., (A) 567
Misra, S., (A) 563
Misson, C. B., (B) 524
Mitchison, D. A., (A) 255
Mittal, M. M., (A) 552
Miyachi, Y., (A) 387
Miyanga, K., (A) 404
Miyata, Y., (A) 582
Mock, B., (A) 390
Modabber, F. Z., (A) 394
Modderman, E. S. M., (A) 387
Modlin, R. L., (C) 361, (A) 596
Mohamed, F. A., (A) 253
Molina, E., (A) 264
Mor, N., (A) 559, 559
Morales, M. J., (A) 579
Morgan, R., (A) 133
Mori, T., (O) 480, (A) 559, 578, 582
Morini, J. C., (A) 249, 249, 395, 402
Morris-Vadal, D., (A) 542
Motta, C. P., (N) 225, (A) 263
Mouly, A., (A) 542
Moya, R., (A) 264
Mshana, R. N., (O) 1, (A) 251, (O) 291, (C) 367, (A) 553
Msibi, V., (A) 566
Mudasia, J., (A) 246
Mukherjee, A., (A) 543, 552
Murray, K. A., (O) 152
Murthy, N., (A) 389
Mustafa, A. S., (A) 547
Mustafa, I. E., (A) 268
Mwankemwa, S. A., (A) 266
Myrvang, B., (A) 397

Naafs, B., (O) 271
Nair, P. R. R., (O) 330
Naka, S. O., (A) 600
Nakagawa, H., (A) 588
Nakajima, S., (A) 404
Nakamura, K., (O) 480, (A) 585, 585, 587
Nakamura, M., (O) 193, (A) 401, (O) 480, (A) 556, 578
Nakano, T., (A) 399
Nakayama, T., (O) 480
Nanda, N. K., (A) 551
Narang, A. P. S., (A) 538
Narang, B. S., (A) 547
Narasimham, M. V. V. L., (A) 545
Nath, I., (A) 132, 244, (O) 297, (A) 551
Nath, V. V. N., (A) 545
Negassi, K., (A) 547
Negrel, A. D., (A) 128
Nelson, K., (A) 601
Nerurkar, C. B., (A) 387
Newfield, S. A., (A) 562
Ng, H., (A) 560, 560
Ng, W. L., (A) 391
Niamien N'Deli, L., (A) 554
Niculescu, D., (A) 399
Nishimake, T., (A) 550
Nishiura, M., (O) 68, (A) 589, 589
Nomaguchi, H., (A) 578
Noussitou, F. M., (B) 125, (A) 561

Nuti, M., (C) 217
Nye, P. M., (A) 253
Nyein, M., (A) 559

O'Connor, R., (B) 383
Ogawa, T., (O) 480, (A) 577
Ohba, N., (A) 248
Ohkawa, S., (A) 562, 595
Ohsawa, (A) 558
Okada, S., (O) 68, 480, (A) 589
Olivares, L. M., (A) 388
Opromolla, D. V. A., (A) 540
Orinda, D. A., (A) 246
Ortiz, M. C., (A) 391, 394
Ortiz, S., (A) 129
Ouaissi, A., (A) 267
Ozaki, M., (A) 387
Ozawa, T., (A) 257, 600

Pacin, A., (A) 398, 542, 543
Packchanian, E., (A) 560
Padmavathi, L., (A) 247
Panayi, G. S., (A) 392
Pandey, A. P., (O) 56
Pandian, P. I., (A) 135
Pasticier, A., (A) 394
Patarroyo, M. E., (A) 264
Patel, M. R., (A) 387, 387
Patel, P. J., (A) 133
Pati, L., (A) 406
Pattyn, S. R., (A) 244, 245, 256, (C) 370, (A) 387, 535, 538
Payne, S. N., (C) 220
Pearson, J. M. H., (O) 31, 425
Pedvis-Leftick, A., (A) 243
Penchenier, L., (A) 392
Pendalwar, S. L., (A) 387
Pettit, J. H. S., (C) 224
Peyri, J., (A) 544, 545
Peyri, L., (A) 544
Pfaltzgraff, R. E., (C) 365
Phadnis, M. C., (O) 143
Pina, N. C., (A) 564
Pinardi, M. E., (O) 415
Pizzariello, G., (A) 388
Podoplelov, I. I., (A) 246
Poli, H., (A) 249, 402
Politzer, W. M., (A) 128
Portaels, F., (A) 256, (C) 370, (A) 387, 408
Porwal, G. L., (A) 249
Potts, R. C., (A) 251
Powell, M. D., (A) 552
Prabhu, S. R., (A) 545
Prabhudass, N., (A) 545
Prasad, H. K., (A) 132, 244
Prasad, K. R., (A) 563
Prasad, S. B., (A) 406, 565
Pratap, V. K., (A) 552
Pratt, P. F., (A) 126
Preston, P. M., (A) 560
Price, J. E., (E) 205
Proenca, N. G., (A) 550
Prome, D., (A) 400
Prome, J. C., (A) 131
Pudifin, D. J., (A) 251
Puglisi, A., (A) 390

Qiang Nengxian, (A) 251

Raina, A., (A) 543
Rajafindrangodona, (A) 127
Rajasekaram, V., (A) 135
Raju, G. D., (A) 404
Ramalingaswami, V., (B) 527
Ramanujam, K., (A) 545
Ramaprasad, K., (A) 545
Ramu, G., (A) 388, 391, 393, 535, 543, 552, 553, 561, 565, 594, 600
Ranade, S. M., (A) 541
Rao, C. K., (A) 545, 545
Rao, K. S., (A) 553
Rao, P. S. S., (A) 563
Rarias, L. R., (A) 550
Rasi, G., (C) 217
Rayyan, W., (A) 554
Razafintsalama, C., (A) 127
Rea, T. H., (O) 164, (C) 361, (A) 392, 596
Recarte, M. C., (A) 389, 389
Reddy, B. S. N., (A) 546
Reddy, B. V., (A) 540
Reddy, N. R., (A) 406
Reddy, P. K., (A) 545
Reddy, R. K., (A) 561
Reddy, S. C., (A) 247
Reddy, V., (A) 135
Rees, R. J. W., (O) 58, (C) 220, (O) 436
Reggiardo, Z., (A) 409
Reich, C. V., (N) 124
Reich, M., (A) 567
Reitan, L. J., (A) 259, (O) 455, (A) 547
Revankar, C. R., (A) 249, 404
Reyes, O., (O) 415
Reyes-Javier, P. D., (N) 233
Rezaev, A. A., (A) 245
Ridel, P. R., (A) 267
Ridley, D. S., (O) 11, (A) 252, (C) 363, (O) 425
Ridley, M. J., (O) 11, (A) 551
Rigdon, R. H., (A) 560
Risso, H. I., (A) 264
Robard, D., (A) 131
Robertson, A. J., (A) 251
Robins, K., (A) 398
Rodriguez, F., (A) 566
Rodriguez-Paez, L., (O) 306
Rojas-Espinosa, O., (O) 306
Rook, G. A. W., (A) 129, 253, 394
Rosa, C., (C) 217
Ross, G. W., (A) 268
Ross, W. F., (C) 214, (N) 377
Rossi Vargas, J., (A) 392
Rotberg, A., (C) 117
Rottoli, L., (A) 134

ROTTOLI, P., (A) 134
ROWE, L., (A) 408
RUBINSTEIN, E., (A) 134
RUBIO, F. C., (A) 546
RUSSELL, D. F., (O) 11, (A) 551

SABATO, S., (A) 129, 247
SABIN, T. D., (A) 126
SABNIS, S. S., (A) 387
SAHA, K., (O) 159, (A) 252, 252, 392
SAHASRANAM, K. V., (A) 546
SAHNI, U., (A) 546
SAIKAWA, K., (A) 264, 563
SAIMOT, G., (A) 394
SAINT-ANDRÉ, P., (A) 267, 554, 565
SAITO, H., (O) 480
SAITO, N., (A) 558
SAKUNTALA, R., (A) 552
SALIBIAN, A., (A) 542
SAMAYOA, J. M., (N) 381
SAMESHIMA, M, (A) 248
SAMUEL, A. M., (A) 567
SAMUEL, E., (A) 543
SAMUEL, N., (A) 253
SANABRIA NEGRIN, J. G., (A) 556
SANADA, K., (A) 577
SANCHEZ, R. M., (O) 177, (A) 396, (O) 488
SANSARRICQ, H., (A) 244, 265, 266, 561
SAOJI, A. M., (A) 247, 557
SARIN, G. S., (O) 322
SAROJINI, P. A., (A) 390
SASAKI, N., (A) 599
SASONETTI, P., (A) 131
SATHISH, M., (A) 244
SATYANARAYANA, K., (A) 135
SAXENA, M. L., (N) 375
SCHAUF, V., (A) 601
SCHIFFERLI, J. A., (A) 127
SCHREUDER, G. M. T., (A) 405
SCHUMAN, J. S., (A) 562
SCOLLARD, D. M., (A) 391, 596, 601
SCOTT, P. A., (A) 409
SEBILLE, A., (A) 565
SEGGIE, J., (A) 546
SEHGAL, S., (A) 543
SEHGAL, V. N., (O) 159, (A) 392
SEMICHENKO, Z. I., (A) 262
SEN, D. K., (O) 322
SENGUPTA, D. N., (A) 395, 396
SENGUPTA, U., (A) 395, 552, 553, 594
SESHADRI, P. S., (A) 244
SESHU, V. C., (A) 135
SETH, V., (A) 268
SEYDEL, J. K., (O) 20, 90
SEYDEL, U., (O) 90
SHAH, J. S., (A) 249
SHANNON, E. J., (A) 552
SHARAFIDDINOV, T. A., (A) 534
SHARMA, A. K., (A) 563
SHARMA, N. K., (A) 552
SHARMA, S. C., (A) 538
SHARMA, S. P., (A) 545
SHARMA, V., (A) 252
SHARMA, V. D., (A) 554
SHARMA, V. K., (O) 159, (A) 392
SHASTRY, J. C. M., (O) 56
SHEPARD, C. C., (O) 96, (A) 245
SHER, R., (A) 128
SHERIF, M. M., (A) 251
SHESKIN, J., (A) 129, 247, 247, (Ob) 508
SHI YUANFU, (O) 316
SHI ZHANGYING, (A) 251
SHIELD, M. J., (O) 436, 446
SHRESTHA, K. B., (N) 123
SHUBIN, V. F., (A) 262
SHULMAN, G., (A) 128
SHUNZHANG, Y., (A) 126
SIDDIQI, S. H., (A) 409
SIDDIQUI, M. A., (A) 252
SILVA, Y., (A) 264
SIMAO, E. T., (O) 325
SINGH, M., (A) 393
SINGH, R., (O) 148
SINHA, M. R., (A) 538
SINHA, S., (A) 552, 553, 594
SINHA, S. N., (C) 219, (O) 468
SKINSNES, O. K., (A) 599
SLANEY, L., (A) 406
SMIRNOVA, T., (A) 556
SMITH, T., (A) 601
SMITH, W. C. S., (A) 538
SOENDIJOJO, A., (A) 405
SONI, N. K., (A) 248
SOTO, I., (A) 393
SPARKS, J., (A) 268
SPINA, A., (A) 554
SREEVATSA, (A) 244
SRINIVASAN, J., (A) 553
SRITHARAN, V., (A) 393, 535, 540, 543
SRIVASTAVA, N. P., (O) 468
STAHL, D., (A) 537
STANFORD, J. L., (A) 129, 253, 394, 398, (O) 436, 446
STANLEY, S. J., (A) 265
STAVRI, D., (A) 399
STAVRI, H., (A) 399
STONE, M. M., (A) 265
STONER, G. L., (O) 1, (A) 253, 553, 553
STORRS, E. E., (O) 83
STROBEL, M., (A) 393
SUBRAHMANYAM, D., (A) 567
SUBRAHMANYAM, V. V. (A) 247
SUGIYAMA, K., (A) 562, 595
SUNDARAM, K. R., (A) 268
SUNDARESAN, T., (A) 561
SUSHIDA, K., (A) 558
SUTHERLAND, I., (A) 265

TAGELDIN, M. H., (A) 268
TAKITANI, S., (A) 244
TALWAR, G. P., (A) 547
TAMONDONG, C. T., (A) 561
TANABE, S., (A) 583

TANEJA, R., (A) 567
TANEMURA, M., (A) 402, 402, 558
TARABINI-CASTELLANI, G., (A) 253
TARABINI-CASTELLANI, G. L., (A) 253
TATSUKAWA, H., (A) 401, (C) 510, (A) 556
TAYLOR, C. R., (C) 361, (A) 596
TAYLOR, P. M., (A) 546
TEN DAM, H. G., (A) 266
TEPPER, B. S., (O) 200
TERENCIO DE LAS AGUAS, J., (A) 546
TEUSCHER, C., (A) 592
THERIZOL-FERLY, M., (A) 392
TIGANO, F., (A) 390
TOKUDOME, S., (A) 248
TONELLO, C. J. S., (A) 540
TORRAS, A., (A) 544, 545
TOUW, J., (A) 253, 553, 553
TRUFFOT, C., (A) 407
TSUTSUMI, S., (A) 244, 386, 589, 590
TUNG, K. S. K., (A) 592
TURCOTTE, R., (O) 494
TURK, J. L., (A) 256
TURKEL, S. B., (O) 164
TURNER, S. M., (A) 556

ULRICH, M., (O) 415
UMLAND, E. T., (A) 592

VACIRCA, E. E., (A) 389, 389
VAIDYA, M. C., (A) 405, 557
VALASQUES, A., (A) 264
VALENTIJN, R. M., (A) 399
VALLES, M., (A) 539
VAN DEN BREEN, L., (A) 387
VAN DROOGENBROECK, J., (A) 554
VAN EDEN, W., (A) 260, 405
VAN ES, L. A., (A) 399
VAN HALE, H. M., (O) 164
VAN LOO, G., (A) 244, 387
VAN LOO, L., (A) 535
VAN PRAAG, E., (A) 266
VAN RENSBURG, C. E., (A) 386, 539
VAN ROOD, J. J., (A) 260, 405
VAQUERO, N. L., (A) 393
VEHORA, S. B., (A) 243
VENKATARAMANAIAH, H. N., (A) 535, 560
VENKATESAN, K., (A) 393, 540, 543
VERAS, J. R., (O) 183
VERMA, K. C., (A) 393
VERMA, R. D., (A) 542
VERROUST, P., (A) 394
VIDYASAGAR, P. B., (A) 401
VIJ, J. C., (O) 148
VIJAYAKUMAR, T., (A) 398
VILHELMSEN, R., (A) 537
VIRDI, B. S., (A) 567
VISHNEVETSKY, F. E., (A) 254, 257
VITHAYASAI, V., (A) 601
VYAS, G. K., (A) 566

WAGNER, H. N., (O) 200
WAHI, P. L., (A) 546
WALL, J. R., (A) 255
WALLACH, D., (O) 282
WALSH, G. P., (A) 267, 385, 584
WALTER, J., (B) 524
WALTERS, B. A. J., (A) 255
WANG DONGHUAI, (A) 251
WANG HEYRING, (A) 126
WANGEL, A. G., (O) 47
WARNDORFF, J., (A) 245
WARNDORFF-VAN DIEPIN, T., (O) 39, 139
WATANUKI, M., (A) 577
WATER, J., (A) 561
WEBER, F. J., (A) 130
WEGELIUS, O., (O) 47
WEINREB, A., (A) 247
WELCH, T. M., (A) 560, 560
WEMAMBU, S. N. C., (C) 117
WEMPE, E. G., (O) 20
WEST, D. P., (A) 243
WHEELER, P. R., (A) 557
WHITTLE, H. C., (A) 390
WOLF, R. H., (A) 267, 584
WON SUK KIM, (A) 549
WORTH, R. M., (O) 335
WOS, J., (A) 128
WRIGHT, G. J., JR., (A) 567
WU QINXUE, (A) 126, 127

XIA MINGYU, (O) 471

YACUB, A. H., (A) 253
YAMADA, K., (A) 599
YAMAURA, N., (A) 399, 595
YAMAZAKI, T., (A) 577
YASUDA, T., (A) 135
YAWALKAR, S. J., (A) 540
YE GAN-YUN, (N) 121, (A) 126, (O) 172, (N) 226, (O) 316, 471, (N) 512
YE SHUNZHANG, (A) 126
YEN LI-ZUNG, (O) 172
YOGI, Y., (A) 585, 586, 587
YONEDA, K., (A) 582, 583
YONG, Z., *et al.*, (A) 131
YONGFA, Z., (A) 126
YOSHIMURA, M., (A) 248
YOSHINO, Y., (A) 257, 600
YOSIPOVICH, Z., (A) 247
YOSIPOVITH, Z., (A) 129

ZAFARULLAH, M., (A) 243
ZAMBRANO, M. T., (A) 129
ZANGRONIZ, L. G., (A) 541
ZANKEL, S., (A) 601
ZHANG YONGFA, (A) 126
ZHOU YONG, (A) 131
ZHU WENYUAN, (O) 471
ZUIDEMA, J., (A) 387

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Acid, fatty
differential metabolism of . . . by mycobacteria. Radiometric measurement of. CAMARGO, E. E., *et al.* ..... (O) 200
exogenous, Effect of growth temperature and, on the lipid composition of *Mycobacterium phlei*. Taneja, R., *et al.* ..... (A) 567

Acid-fast characteristics,
acid-fast bacilli in skin smears of leprosy patients. A study of selection sites for. Kim, Y. ..... (A) 391
non-cultivable acid-fast bacilli in the environment and their relationship to *M. leprae*. Occurrence of. Kazda, J. ..... (A) 262
oxidative acid-fast staining for non-deparaffinized sections of leprosy tissue. A modified procedure of. Yong, Z., *et al.* ..... (A) 131

Africa,
BCG vaccination of children against leprosy in Uganda: final results. Stanley, S. J., *et al.* ..... (A) 265
epidemiological situation in. Cap, J. A. ..... (A) 258
Field experience for doctors (Malawi). ..... (N) 232
paramedicals, employment sought for. ..... (N) 119
Prevalence of dapsone-resistant leprosy to the Burundi. Bourland, J., *et al.* ..... (A) 535
Serum lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* ..... (A) 246

Albania,
leprosy situation in. Lechat, M. F. ..... (N) 119

American Leprosy Missions (ALM),
Emmanuel Faria named to . . . Board. ..... (N) 521
International seminars on leprosy sponsored by . . . and National Hansen's Disease Center. ..... (N) 381

Antibody(ies),
absence of, to muramyl dipeptide in patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..... (A) 394
—, responses of leprosy patients to *Mycobacterium leprae* glycolipid-1 antigen. Umland, E. T., *et al.* ..... (A) 592
— studies in leprosy and experimental models of the disease, significance of. HARBOE, M. ..... (E) 342
— to sulfolipids in human leprosy sera. KHULLER, G. K., *et al.* ..... (O) 319
anticollagen type I and II . . . by an immunoenzymatic technique (ELISA), Detection of: results in rheumatoid arthritis, systemic lupus erythematosus and leprosy. Meghlaoui, A. ..... (A) 250
antispermatozoal, in leprosy. A study of. GUPTA, S. C., *et al.* ..... (O) 43
class specific anti-*Mycobacterium leprae* . . . assay in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* ..(O) 271
demonstration of specific antibodies to *Mycobacterium leprae* by counter current electrophoresis. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. .....(A) 396
fluorescent leprosy . . . absorption (FLA-ABS) test for early serodiagnosis of leprosy. Bharadwaj, V. P., *et al.* ..... (A) 388
—, —, —, —, —, —, Subclinical infection in leprosy; its detection and control by. Abe, M., *et al.* ..... (A) 257
IgA and IgM . . . against *Mycobacterium leprae* in cord sera and in patients with leprosy: an indicator of intrauterine infections in leprosy. Melsom, R., *et al.* .....(A) 397
immunoglobulin class specific . . . in *M. leprae* in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Melsom, R., *et al.* ..... (A) 397

—, G and M . . . responses to *Mycobacterium leprae* in relation to various disease patterns. Humoral immunity in leprosy. Touw, J., *et al.* .....(A) 553
monoclonal, Antigenic diversity of *Mycobacterium tuberculosis* and *Mycobacterium bovis* detected by means of. Coates, A. R. M., *et al.* .....(A) 255
—, production and initial characterization of, to *Mycobacterium leprae*. Immunochemical characterization of antigens of the leprosy bacillus, including. Miller, R. A., *et al.* .....(A) 593
—, —, and partial characterization of, to *Mycobacterium leprae*. Gillis, T. P. and Buchanan, T. M. .....(A) 547
—, T lymphocyte subpopulations defined by. Thymus dependent lymphocytes in leprosy. MSHANA, R. N., *et al.* .....(O) 291
specific . . . to *Mycobacterium leprae* by counter current electrophoresis, Demonstration of. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. .....(A) 396

Antigen(s),
— of the leprosy baccillus, Immunochemical characterization of, including production and initial characterization of monoclonal antibodies to *Mycobacterium leprae*. Miller, R. A., *et al.* .....(A) 593
— of mycobacteria, groups of shared or species specific, A preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to. Stanford, J. L., *et al.* .....(A) 253
— -specific reactions and resistance to *Mycobacterium lepraemurium* infection in mice, A lack of correlation between. Curtis, J., *et al.* .....(A) 256
—, —, suppressor cells in subclinical leprosy infection. Stoner, G. L., *et al.* .....(A) 253
— stimulated human lymphocyte by histamine, Specific modulation of. Nanda, N. K. and Nath, I. .....(A) 551
Antigenic analysis of *M. leprae* in lepromins with reference to the delayed type of hypersensitivity. Sengupta, U., *et al.* .....(A) 594
Antigenic diversity of *Mycobacterium tuberculosis* and *Mycobacterium bovis* detected by means of monoclonal antibodies. Coates, A. R. M., *et al.* .....(A) 255
armadillo, Correlation between early (Fernandez) and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of, in three double-blind trials. Bechelli, L. M., *et al.* .....(A) 547
circulating . . . in onchocerciasis, Detection of. Ouaissi, A., *et al.* .....(A) 267
Dharmendra, Assessment of. (V) Attempts for purification of specific skin delayed hypersensitivity (DH) inducing . . . from lepromin. Sengupta, U., *et al.* .....(A) 552
(VI). Skin tests with fractionated nucleic acids. Sinha, S., *et al.* .....(A) 553
Leprosy ELISA . . . coating buffers and antigens: comparison of *M. leprae* whole organisms with other mycobacteria. Naka, S. O. and Douglas, J. T. .....(A) 600
most immunologically reactive . . . from *Mycobacterium tuberculosis* H37Ra culture filtrate, Isolation and partial characterization of. Reich, M., *et al.* .....(A) 567
mycobacterial . . . of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy, Prostaglandin-dependent regulation of the *in vitro* proliferative response to. Bahr, G. M., *et al.* .....(A) 129
mycobacterial, in leprosy tissues, Demonstration of. MSHANA, R. N., *et al.* .....(O) 1
Mycobacterium leprae, effect of dapsone treatment on the response to, tuberculin purified protein derivative and non-mycobacterial stimulants. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* .....(O) 455
—, —, glycolipid-1, Antibody responses of leprosy patients to. Umland, E. T., *et al.* .....(A) 592
Mycobacterium lepraemurium . . . at the infection site, Repeated delayed-type hypersensitivity reaction against, do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. .....(A) 397
Mycobacterium smegmatis peroxidase, cross-reacting . . . with *Mycobacterium leprae*. Stavri, D., *et al.* .....(A) 399
purified . . . of *M. leprae* and tuberculin PPD, *In vitro* lymphocyte stimulation using. Closs, O. and Reitan, L. J. .....(A) 259
soluble cytoplasmic mycobacterial, Double blind trial on the effect of certain, on the late reactivity to lepromin. HADDAD, N., *et al.* .....(O) 325

specific phenolic glycolipid . . . and a related diacyl phthioceral in secretions from *Mycobacterium leprae*, Structure and antigenicity of. Hunter, S. W., *et al.* .....(A) 591
tuberculous, Radioimmunoassay of. Kadival, G. V., *et al.* .....(A) 567

Argentina,
Argentine Society of Leprosy annual activities. .....(N) 511
Leprosy in the Northeast (Zone I). Risso, H. I. .....(A) 264
Premio Jose M. M. Fernandez. .....(N) 119

Armadillo,
An appetite for. Freiberger, H. F. and Fudenberg, H. H. .....(A) 128
— antigen in three double-blind trials, Correlation between early (Fernandez) and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of. Bechelli, L. M., *et al.* .....(A) 547
— derived *Mycobacterium leprae*, epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from. Part 1. Leprosy patients. SHIELD, M. J., *et al.* .....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. .....(O) 446
—, experimentally infected, Borderline leprosy in. JOB, C. K., *et al.* .....(O) 488
—, —, —, Lipidic constituents of *Mycobacterium leprae* isolated from. Asselineau, C., *et al.* .....(A) 131
— lepromin in 50 leprosy patients, comparative study with whole human and. Mitsuda reaction. Zambrano, M. T., *et al.* .....(A) 129
— liver, Superoxide dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with. Wheeler, P. R. and Gregory, D. .....(A) 557
— livers infected with *Mycobacterium leprae*, Isolation of fastidiously growing mycobacteria from. PORTAELS, F. and PATTYN, S. R. .....(C) 370
frozen (−80°C) . . . tissue, Uptake of 3,4-dihydroxy[3H]phenylalamine by *Mycobacterium leprae* isolated from. Khanolkar, S. R., *et al.* .....(A) 555
Multibacillary leprosy in unaltered hosts, with emphasis on . . . and monkeys. Meyers, W. M., *et al.* .....(A) 584
purified . . . derived *Mycobacterium leprae* in man, Testing of, IMMLEP. .....(N) 378
Resistance against leprosy in . . . intraspecies differences of Dharmendra. .....(A) 250
—, —, —, in nine-banded . . ., Intraspecies differences of. Kirchheimer, W. F. and Sanchez, R. M. .....(A) 396
Tissue response to lepromin, an index of susceptibility of the . . . to *M. leprae* infection; a preliminary report. JOB, C. K., *et al.* .....(O) 177

Assay(s) (*see also* ELISA),
beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a further probe into cholesterol metabolism, Indirect . . . of. Kannan, K. B., *et al.* ..(A) 542
Class specific anti-*Mycobacterium leprae* antibody . . . in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* .....(O) 271

Australia,
Change in leprosy control policy. Hargrave, J. C. .....(N) 511
Leprosy amongst the Aboriginals, (Letter to the Editor). McNulty, J. C. .....(A) 562

B663,
ILEP information on side-effects from clofazimine. .....(N) 223

Bacilli,
acid-fast, in skin smears of leprosy patients, A study on selection of sites for. Kim, Y. .....(A) 391
bacilliferous leprosy patients, Close contacts and non-contacts of. Epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from armadillo-derived *Mycobacterium leprae*. Part 2. SHIELD, M. J. and STANFORD, J. L. .....(O) 446
human and murine leprosy, Ultrastructural features of the multiplication of, in macrophages of nude mice. FUKUNISHI, Y., *et al.* .....(O) 68

killed ICRC, Potential antileprosy vaccine from, a clinicopathological study. Deo, M. G., *et al.* ....(A) 130
leprosy, Cytology of. Hirata, T. ....(A) 577
—, Immunochemical characterization of antigens of, including production and initial characterization of monoclonal antibodies to *Mycobacterium leprae*. Miller, R. A., *et al.* ....(A) 593
morphology of . . . at different levels of the dermal infiltrate in lepromatous leprosy. GIRDHAR, B. K. and MCDOUGALL, A. C. ....(O) 477
murine leprosy, Mitogen-induced DNA synthesis in various mouse strains infected with a large or small dose of. Yamaura, N., *et al.* ....(A) 399
—, —, Phospholipid deacylating activities in. Kashiwabara, Y. and Nakagawa, H. ....(A) 588
non-cultivable acid-fast, Occurrence of, in the environment and their relationship to *M. leprae*. Kazda, J. ....(A) 262
normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy, Cutaneous response to. Corona, C. J. J., *et al.* ....(A) 249
Repeated delayed-type hypersensitivity reaction against *Mycobacterium lepraemurium* antigens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. ....(A) 397

Bacteriology,
bacteriologically positive leprosy cases, study of 922. KOTICHA, K. K., *et al.* ....(O) 330
nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., *et al.* ....(O) 58
present data on the . . . of leprosy. Grosset, J., *et al.* ....(A) 555

BCG (bacille Chalmette-Güerin),
— and levamisole injection in lepromatous leprosy patients, A study on histopathological change of leproma after. Kim, D. ....(A) 396
— vaccine-induced lupus vulgaris. Izumi, A. K. and Matsunaga, J. ....(A) 407
Immunotherapy with a mixture of *Mycobacterium leprae* and . . . in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., *et al.* ....(O) 415
in preschool children, Delayed hypersensitivity after, in relation to their nutritional status. Seth, V., *et al.* ....(A) 268
Mycobacterium bovis, and *Mycobacterium leprae*, Ultrastructural characteristics of. BINKHUYSEN, F. and DAS, P. K. ....(O) 76
— —, . . . vaccination upon *Mycobacterium lepraemurium* infection, Effect of. Lefford, M. J., *et al.* ....(A) 133
— —. Lack of a sustained protection against murine leprosy in C3H mice vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with. TURCOTTE, R. and LEMIEUX, S. ....(O) 494
vaccination in leprosy. PRICE, J. E. ....(E) 205
vaccination of children against leprosy in Uganda: final results. Stanley, S. J., *et al.* ..(A) 265

Belgium,
The Leper Quarterly collection. Lechat, M. F. ....(N) 511

Beta-glucuronidase,
Immunohistopathologic study of . . . and lysozyme in human leprosy skin lesions. Matsuo, E., *et al.* ....(A) 599

Biochemistry,
M. vaccae with *M. leprae*. Biochemical correlation of. Dutta, A. K., *et al.* ....(A) 554
peribacillary substance of *M. leprae*. Biochemical study of. Fukunishi, Y., *et al.* ....(A) 589

Blood,
— lactic and pyruvic acids in leprosy, Effect of dapsone on. SINHA, S. N., *et al.* ....(O) 468
— staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., *et al.* ....(A) 248
mycobacterial antigens of peripheral . . . lymphocytes from normal donors and from patients with tuberculosis of leprosy, Prostaglandin-dependent regulation of the *in vitro* proliferative response to. Bahr, G. M., *et al.* ....(A) 129

normal . . . donors of three races, Circulating immune complexes in. Pudifin, D. J. and Duursma, J. .....(A) 251
of lepromatous patients with erythema nodosum leprosum, Pharmacologically active mediators of hypersensitivity reactions in. Saha, K. and Lahiri, S. C. .....(A) 252
peripheral . . . and tissues of patients with leprosy, T cell subsets in. Modlin, R. L., *et al.* .....(A) 596
—, —, T and B lymphocytes in leprosy, study of. Hee Chul Eun, *et al.* .....(A) 549
rabbit red . . . cell rosette formation method, On the immunodepressive effect of rifampicin (RFP) on cell-mediated immunity of guinea pigs examined by. Gidoh, M. and Tsutsumi, S. .....(A) 386
transfusions of fresh . . . donated by healthy but lepromin positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated. Saha, K *et al.* .....(A) 552

Borderline leprosy,
in an experimentally infected armadillo. JOB, C. K., *et al.* .....(O) 488
tuberculoid, in reaction presenting as photodermatitis: case report. Fekete, E., *et al.* ..(A) 390
—, *In vitro* lymphocyte stimulation in patients with lepromatous and, effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* ..(O) 455

Bowel,
Structure and function of the small . . . in lepromatous leprosy. KUMAR, N., *et al.* ...(O) 148
toxicity of clofazimine with special reference to structural and functional status of small intestine, Study of. Kumar, B., *et al.* .....(A) 537

Brazil,
incidence of Hansen's disease in the state of Sao Paulo in 1978. Belda, W. and Lombardi, C. A. .....(A) 257
severe dermatitis induced by the use of thiacetazone in the treatment of tuberculosis in the state of Rio Grande do Sul. .....(A) 243
status of leprosy in Rio Grande do Sul. .....(A) 133

Bulgaria,
Leprosy in. Mikhailov, P. and Dimitrova, I. .....(A) 403

Burma,
epidemiological evaluation in, . . . of the skin test reagent LRA6; a cell-free extract from armadillo derived *Mycobacterium leprae*. Part 1. Leprosy patients. SHIELD, M. J., *et al.* .....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. .....(O) 446
epidemiological information on leprosy in the Singu area of Upper Burma. Dominguez, V. M., *et al.* .....(A) 561
Tenth meeting of THELEP Steering Committee held in Rangoon. .....(N) 225

Cancer,
— and other causes of death among leprosy patients. Tokudome, S., *et al.* .....(A) 248

Cape Verde,
Leprosy in. Loretti, A. and Garbellini, D. .....(A) 263

Cefoxitin,
In vitro susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonei* to. Casal, M. and Rodriguez, F. .....(A) 566

Cell(s),
Antigen-specific suppressor, in subclinical leprosy infection. Stoner, G. L., *et al.* .....(A) 253
B . . . alloantigen associated with susceptibility to lepromatous leprosy, Identification of. Patarroyo, M. E., *et al.* .....(A) 264
— culture under regulation of redox potential at environment, Attempts at cultivation of *Mycobacterium leprae* in. Matsuo, Y. and Tatsukawa, H. .....(A) 556
—, —, Use of cycloheximide of cultivating *Mycobacterium leprae* and *Mycobacterium lepraemurium* in. Matsuo, Y. .....(A) 578

— free extract from armadillo-derived *Mycobacterium leprae*, epidemiological evaluation. in Burma, of the skin test reagent LRA6. Part 1. Leprosy patients. SHIELD, M. J., *et al.* .....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. .....(O) 446
—, —, liquid medium by aspartic acid, sucrose, liposome, thymidine, and deoxyuridine (NDLASU medium), Stimulation of growth of *Mycobacterium lepraemurium* in. Nakamura, M. .....(A) 578
—, —, —, by DL-aspartic acid, Stimulation of growth of *Mycobacterium lepraemurium* in. NAKAMURA, M. .....(O) 193
—, —, —, by vitamin K3 and B12, Growth stimulation of *Mycobacterium lepraemurium* in. Nakamura, M. .....(A) 401
—, —, —, Effect of pantoyl lactone on the growth of *Mycobacterium lepraemurium* in. Nakamura, M. .....(A) 556
— mediated and humoral immunity during pregnancy and lactation, Preganacy and leprosy: consequence of alterations of. DUNCAN, M. E., *et al.* .....(O) 425
—, —, immunity, effect of body temperature and, on the growth of *Mycobacterium marinum* and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* .....(A) 556
—, —, —, in lepromatous leprosy using HLA-D-identical siblings, Studies on the defect in. Absence of circulating suppressor . . . and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* .....(A) 553
—, —, —, of guinea pigs examined by rabbit red blood . . . rosette formation method, On the immunodepressive effect of rifampicin (RFP) on. Gidoh, M. and Tsutsumi, S. .....(A) 386
— wall components of microorganisms isolated from human leprosy lesions, Chemical identification of. Janczura, E., *et al.* .....(A) 401
cellular and humoral anti-infective factors, Decreased, in the breast secretions of lactating mothers with lepromatous leprosy. Saha, K., *et al.* .....(A) 252
immunological implications of necrotic, cellular and vascular changes in leprous neuritis: light and electron microscopy. Dastur, D. K., *et al.* .....(A) 400
intra-cellular mycobacteria in experimental mouse tuberculosis, electron microscopy study of. Kanai, K., *et al.* .....(A) 135
Langerhans', in leprosy, Preliminary observation on. LIU JIHE, *et al.* .....(O) 316
mononuclear . . . infiltrates in dermal lesions of leprosy, *in situ* characteristics of. GUPTA, S. K., *et al.* .....(O) 297
mycobacterial, A fluorescent staining procedure for determining the viability of. KVACH, J. and VERAS, J. R. .....(O) 183
plasma . . . dyscrasia, Renal amyloidosis complication of tuberculoid leprosy and, case reports of three patients. Seggie, J. and Gelfand, M. .....(A) 546
pre-S-phase . . . cycle kinetics of mitogen-stimulated normal human lymphocytes, Serum inhibitory factor in lepromatous leprosy; its effect on. Potts, R. C., *et al.* ..(A) 251
single bacterial, Detection of externally induced impairments in, by laser microbe mass analysis. SEYDEL, U., *et al.* .....(O) 90
splenic, of such vaccinated mice, Inhibition of foot pad multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of. Bhide, M. B., *et al.* .....(A) 400
stabilized sensitized red, Indirect hemagglutination test with. Serology of leprosy. I. Jagannath, C. and Sengupta, D. N. .....(A) 395
Suppressor, in experimental murine leprosy. Akiyama, T., *et al.* .....(A) 595
suppressor mechanisms in leprosy, An investigation of. Shannon, E. J., *et al.* .....(A) 552
T . . . subpopulations in lepromatous leprosy, Imbalances in. WALLACH, D., *et al.* .....(O) 282
T . . . subsets in the peripheral blood and tissues of patients with leprosy. Modlin, R. L., *et al.* .....(A) 596
thymus, effects of carrageenans, splenectomy, and treatment with. The nude rat as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. .....(A) 587
tissue culture, relationship between pathogenicity in mice and the ability of *M. lepraemurium* to grow in. Nomaguchi, H. *et al.* .....(A) 578

Ultrastructures of, in lesions of lepromatous and tuberculoid leprosy. Liu Zijun, *et al.* .....(A) 551

Chemotaxis,
of monocytes in hanseniasis. AZULAY, R. D. .....(C) 215
polymorphonuclear leukocyte (PMN), Thalidomide does not affect. Miyachi, Y. and Ozaki, M. .....(A) 387

Chemotherapy,
combined . . . against *M. leprae,* A model for the development of. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. SEYDEL, J. K. and WEMPE, E. G. .....(O) 20
in pulmonary tuberculosis, Shortest possible acceptable, effective ambulatory. Mehrotra, M. L., *et al.* .....(A) 408
of leprosy (Editorial). .....(A) 535
—, —, (Letter to the Editor). Smith, W. C. S. .....(A) 538
—, —, for control programmes. .....(A) 536
—, —, in nude mice. Effect of dapsone (DDS) on nude mice experimentally infected with *Mycobacterium leprae.* Yoneda, K., *et al.* .....(A) 582
multi-drug . . . of leprosy and type 1 reaction, Short-term. PFALTZGRAFF, R. E. .....(C) 365
Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. .....(N) 124

Child(ren),
BCG in preschool, Delayed hypersensitivity, in relation to their nutritional status. Seth, V., *et al.* .....(A) 268
—, vaccination of, against leprosy in Uganda: final results. Stanley, S. J., *et al.* .....(A) 265
early (Fernandez) and late (Mitsuda) reactions in, and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials, Correlation between. Bechelli, L. M., *et al.* .....(A) 547
hypo-pigmented lesions in, A study of. Dutta, R. K. and Murthy, N. .....(A) 389
Leprosy in. Noussitou, F. M. .....(B) 125
of patients with indeterminate leprosy, tuberculoid leprosy, and lepromatous leprosy, Specific skin test responses in. Gimenez, M. and Morini, J. C. .....(A) 395

China, People's Republic of,
Chinese leprologist delegation returned to Bijing after round-the-world investigative tour of eight countries. Ye Gan-yun. .....(N) 512
Juzam (leprosy) and its treatment in Unani medicine. Zafarullah, M., *et al.* .....(A) 243
Leprosy in Guangdong Province basically under control. Ma Haide. .....(N) 225
National Technical Symposium on Leprosy control held in Nanjing. Ye Gan-yun. .....(N) 226
Second National Leprosy Conference held in Guangzhou. Ye Gan-yun. .....(N) 121

Cholesterol,
— metabolism, Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a further probe into. Kannan, K. B., *et al.* .....(A) 542

Chromatography,
high performance liquid, Determination of three main antileprosy drugs and their main metabolites in serum by. Gidoh, M., *et al.* .....(A) 244
thin-layer chromatographic analysis of whole-organism methanolysates, Identification of *Mycobacterium chelonei* by. Goodfellow, M. and Minnikin, D. E. .....(A) 267

Classification, of leprosy,
— and treatment of neuropathy in Hansen's disease. Charosky, C. B. .....(A) 267
Correlation of clinical and histopathological studies in. Dubey, G. K., *et al.* .....(A) 389
Diversities in clinical and histopathological. Jerath, V. P. and Desai, S. R. .....(A) 542
pathogenesis and classification of polar tuberculoid leprosy. Ridley, D. S. .....(A) 252

Clinical,
— activity of erythema nodosum leprosum, Immune complexes in leprosy patients from an endemic and nonendemic area and a longitudinal study of the relationship between complement breakdown products and the. Valentijn, R. M., *et al.* .....(A) 399

— and epidemiological features of leprosy in two resettlement villages (Thailand). Vithayasai, V., *et al.* ....(A) 601
— and experimental studies on sulfone resistant leprosy. Li Wenzhong, *et al.* ....(A) 126
— and histopathological classification of leprosy, Diversities in. Jerath, V. P. and Desai, S. R. ....(A) 542
—, —, evaluation, Kveim test in leprosy. Kaur, S., *et al.* ....(A) 246
—, —, studies in classification of leprosy, Correlation of. Dubey, G. K., *et al.* ....(A) 389
— diagnosis of dapsone-resistant leprosy. Taylor, P. M. ....(A) 546
— evaluation of orofacial lesions of leprosy. Prabhu, S. R. and Daftary, D. K. ....(A) 545
— practice, Applicability of Ridley-Jopling scale in. Verma, K. C., *et al.* ....(A) 393
clinico-pathological study of so-called immune zones in leprosy. Sahni, U., *et al.* ....(A) 546
—, —, of testicular involvement in leprosy. Kumar, B., *et al.* ....(A) 543
distinct . . . forms of leprosy, Cutaneous response to normal bacillary lepromin incubated with sera from patients with. Corona, C. J. J., *et al.* ....(A) 249
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy. Panayi, G. S. ....(A) 392
indeterminate leprosy; a valid . . . concept. BROWNE, S. G. ....(C) 221
Leprosy of the Upper Respiratory Tract. Atlas of Clinical Picture and Notes on the Research (1938–1943). Yosie, Y. ....(B) 384
Medical Assistance Programs (MAPS) fellowships provide mission experience. ....(N) 234
microcirculation of the nail folds of leprosy, Study of. Hua Wenyuan, *et al.* ....(A) 549
potential antileprosy vaccine from killed ICRC bacilli; a clinico-pathological study. Deo, M. G., *et al.* ....(A) 130
short-term . . . trials monitored by mouse foot pad inoculation, A brief review of experiences with. Shepard, C. C. ....(A) 245
— spectrum of hanseniasis, Hepatic functions in relation to the. Pacin, A., *et al.* ....(A) 543
sub-clinical infection in leprosy, Detection of (Editorial). Dharmendra. ....(A) 561
—, —, —, in household contacts in India; a preliminary report, Immunoepidemiological studies on. Bharadwaj, V. P., *et al.* ....(A) 600
—, —, —, its detection and control by fluorescent leprosy antibody absorption (FLA-ABS) test. Abe, M., *et al.* ....(A) 257
—, —, —, a preliminary report on. Bharadwaj, V. P., *et al.* ....(A) 561
—, —, with *M. leprae*, Immunoepidemiological studies on. III. Geographic distribution of FLA-ABS test positive responders with special reference to their possible source of infection. Abe, M., *et al.* ....(A) 600
—, leprosy infection, Antigen-specific suppressor cells in. Stoner, G. L., *et al.* ....(A) 253

Clofazimine (B663, Lamprene®),
activity of, against *Mycobacterium intracellulare*, Dynamic aspects of. Gangadharam, P. R., *et al.* ....(A) 126
— resistant leprosy; a case report. WARNDORFF-VAN DIEPEN, T. ....(O) 139
— therapy, Vitamin A levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without. Bharadwaj, V. P., *et al.* ....(A) 535
effects of . . . alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Van Rensburg, C. E., *et al.* ....(A) 539
—, on the motility of neutrophils and transformation of lymphocytes from normal individuals, *in vitro* and *in vivo*. Gatner, E. M. S., *et al.* ....(A) 386
in pregnancy complicated by leprosy. Farb, H., *et al.* ....(A) 243
metabolism of, in leprosy patients. Feng, P. C. C., *et al.* ....(A) 385
new urinary metabolite of, in leprosy patients. Feng, P. C. C., *et al.* ....(A) 536
side-effects from, ILEP information on. ....(N) 233
Three drugs used most frequently for leprosy are dapsone, rifampin and. ....(N) 235
toxicity of, with special reference to structural and functional status of small intestine, Study of. Kumar, B., *et al.* ....(A) 537

Colombia,
Fifth Congress of Tropical Disease. ....(N) 513

Complement,
Dapsone and. Schifferli, J. A. and Jones, R. R. ....(A) 127
Genetic polymorphisms of properdin factor B(Bf), the second component (C2) and

the fourth component (C4) of, in leprosy patients and healthy controls from Thailand. Greiner, J., *et al.* ....(A) 130
in leprosy, Immune complexes and. Geniteau, M., *et al.* ....(A) 394
relationship between . . . breakdown products and the clinical activity of erythema nodosum leprosum, Immune complexes in leprosy patients from an endemic and nonendemic area and a longitudinal study of. Valentijn, R. M., *et al.* ....(A) 399

Control, of leprosy,
by fluorescent leprosy antibody absorption (FLA-ABS) test, Subclinical infection in leprosy; its detection and. Abe, M., *et al.* ....(A) 257
Change in leprosy control policy (Australia). Hargrave, J. C. ....(N) 511
control in Muheza District (Tanzania), a prevalence survey on leprosy and the possible role of village 10-cell leaders. Von Praag, E. and Mwankemwa, S. A. ....(A) 266
— programmes, Surgical problems of acute onset in leprosy patients and their management in. Prasad, S. B. ....(A) 565
— renewed effort by the government of India. Saxena, M. L. and Johnsen, D. O. ....(N) 375
control of specificity of skin test reagents. Magnusson, M. ....(A) 263
control programmes, Chemotherapy of leprosy for. ....(A) 536
Fourth International Workshop on Leprosy Control in Asia, Kuala Lumpur site of. Lechat, M. F. ....(N) 515
General health education as the main approach to. Hogerzeil, L. M. and Reddy, R. K. ....(A) 561
Genetic polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from Thailand. Greiner, J., *et al.* ....(A) 130
HLA-linked control of the course of *M. leprae* infections. de Vries, R. R. P., *et al.* ..(A) 260
immunomodulative, by pharmacotherapeutic means, Fundamental studies on. Tsutsumi, S. and Gidoh, M. ....(A) 589
in Surabaya (Indonesia). Soendijojo, A., *et al.* .... A) 405
Leprosy eradication in the developing countries; the required necessary foundation. WEMAMBU, S. N. C. ....(C) 117
Leprosy in Guangdong Province (China) basically under control. Ma Haide. ....(N) 225
National Technical Symposium on Leprosy control held in Nanjing (China). Ye Ganyun. ....(N) 226
Tuberculosis control: a world review ....(A) 568
Urban Leprosy Control. WHO workshop, Bombay (India). ....(B) 383
Workshop on National Leprosy Control Programme of Varansi Region (India). ....(N) 230

Corynebacterium,
deoxyribonucleic acids of, isolated from human leprosy lesions and of related microorganisms, Base compositions and homologies of. Danhaive, P., *et al.* ....(A) 256

Costa Rica,
Diffuse lepromatous leprosy in. Castro-Coto, A. and Hidalgo-Hidalgo, H. ....(A) 388
Nodular tuberculoid leprosy in. Hidalgo-Hidalgo, H. and Castro-Coto, A. ....(A) 390

Criggler-Najjar,
Gilbert's syndrome, with Hansen's disease of the dimorphous type. BANERJEE, K. ...(C) 509

Cuba,
Epidemiologic characteristics of leprosy. A study of the prevalence in the City of Santa Clara. Gonzalez, A. N. and Apolinaire Pennin, J. J. ....(A) 260
Serology to determine syphilis in Hansen's disease patients at Plaza Municipality during 1977. Cardenas, Z. L., *et al.* ....(A) 541

Cultivation,
—, the neglected priority. KATO, L. ....(C) 368
—, of *Mycobacterium leprae* and *Mycobacterium lepraemurium* in cell culture. Use of cycloheximide for. Matsuo, Y. ....(A) 578
—, —, —, —, in cell culture under regulation of redox potential at environment, Attempts at. Matsuo, Y. and Tatsukawa, H. ....(A) 556
—, —, —, *lepraemurium in vitro,* and its identification by animal inoculation. Ishaque, M. ....(A) 132

non-cultivable acid-fast bacilli in the environment and their relationship to *M. leprae*, Occurrence of. Kazda, J. ....(A) 262

Cutaneous,
allergic . . . vasculitis; Lucio phenomenon. The spectrum of the necrotizing lepra reactions. A proposed intermediate lepra reaction. Peyri, L., *et al.* ....(A) 545
— leishmaniasis, experimental: disseminated leishmaniasis in genetically susceptible and resistant mice. Scott, P. A. and Farrell, J. P. ....(A) 409
— response to normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy. Corona, C. J. J., *et al.* ....(A) 249
disseminated . . . rhinosporidiosis treated with dapsone, Case reports. Mahakrisnan, A., *et al.* ....(A) 135

Cycloheximide,
for cultivating *Mycobacterium leprae* and *Mycobacterium lepraemurium* in cell culture, Use of. Matsuo, Y. ....(A) 578

Damien-Dutton Award,
Robert Watelet is presented with the 1980. Ross, W. F. ....(N) 377

Dapsone (DDS),
and complement. Schifferli, J. A. and Jones, R. R. ....(A) 127
blood lactic and pyruvic acids in leprosy, Effect of . . . on. SINHA, S. N., *et al.* ....(O) 468
clofazimine alone or combined with . . . on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy, Effects of. Van Rensburg, C. E., *et al.* ....(A) 539
— monotherapy for varying periods of time, The nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with. BARTON, R. P. E., *et al.* ....(O) 58
— resistant leprosy, clinical diagnosis of. Taylor, P. M. ....(A) 546
—, —, —, Co-incident (simultaneous) . . . sensitive and. MCDOUGALL, A. C. and ROSS, W. F. ....(C) 214
—, —, —, in Korea. Kim, D. ....(A) 386
—, —, —, in Upper Volta, Four cases of. Pattyn, S. R., *et al.* ....(A) 244
—, —, —, Prevalence of, to the Burundi (Africa). Bourland, J., *et al.* ....(A) 535
—, —, —, The problem of: diagnosis and management. Laing, A. B. G. ....(A) 244
—, —, *Mycobacterium leprae*, Increase in prevalence of leprosy caused by. ....(N) 234
—, —, —, —, Rapid macrophage culture method for detection of. Nath, I., *et al.* ....(A) 244
— treatment, Class specific anti-*Mycobacterium leprae* antibody assay in lepromatous leprosy (BL-LL) patients during the first two to four years of. MELSOM, R., *et al.* ....(O) 271
—, —, on the response to *Mycobacterium leprae* antigens, The effect of, tuberculin purified protein derivative and non-mycobacterial stimulants. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* ....(O) 455
disseminated cutaneous rhinosporidiosis treated with, Case reports. Mahakrisnan, A., *et al.* ....(A) 135
Fixed genital drug eruption due to. Sinha, M. R. ....(A) 538
in initial treatment of lepromatous leprosy, Once-monthly rifampicin plus daily. Yawalkar, S. J., *et al.* ....(A) 540
in protein deficiency, Disposition of; an experimental study in mice. Venkatesan, K., *et al.* ....(A) 540
Intramuscular infection of . . . in therapy for leprosy: A new approach. Modderman, E. S. M., *et al.* ....(A) 387
isoniazid, prothionamide and . . . against *Mycobacterium leprae* and some other mycobacteria, Activity of the combination of. Pattyn, S. R., *et al.* ....(A) 387
nude mice experimentally infected with *Mycobacterium leprae*, Effect of . . . on. The study of leprosy chemotherapy in nude mice. Yoneda, K., *et al.* ....(A) 582
paucibacillary leprosy resistant to, Two cases of. Janssens, L. ....(A) 537
phytohaemagglutinin (PHA)-induced lymphocyte transformation, *In vitro* effect of . . . on. Ghei, S. K., *et al.* ....(A) 395
pig's thymosin combined with, Pilot-trial of treatment of leprosy by. ....(A) 551

serum, and serum level of . . . in 87 leprosy patients, Method of determining. Qin-Xue, W., *et al.* .....(A) 127
Three drugs used most frequently for leprosy are . . ., rifampin and clofazimine. .....(N) 235

Deformities,
leprosy . . . in a closed community, A survey of. Prasad, S. B. .....(A) 406

Deoxyribonucleic acid (DNA),
base compositions and homologies of . . . of corynebacteria isolated from human leprosy lesions and of related microorganisms. Danhaive, P. *et al.* .....(A) 256
isolated from *Mycobacterium leprae*: genome size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation. Imaeda, T., *et al.* .....(A) 400
mitogen-induced . . . synthesis in various mouse strains infected with a large or small dose of murine leprosy bacilli. Yamaura, N., *et al.* .....(A) 399

Dermatoglyphics,
digital, Features of, in leprosy patients. Baranov, Y. N. and Podoplelov, I. I. .....(A) 246
in tuberculoid leprosy, Study of. Kapur, T. R. and Verma, R. D. .....(A) 543

Dermatology,
dermal infiltrate in lepromatous leprosy, morphology of bacilli at different levels of. GIRDHAR, B. K. and MCDOUGALL, A. C. .....(O) 477
—, lesions of leprosy, *in situ* characteristics of mononuclear cell infiltrates in. GUPTA, S. K., *et al.* .....(O) 297
—, microvasculature in leprosy, Ultrastructure of. TURKEL, S. B., *et al.* .....(O) 164
dermatitis, severe, induced by the use of thiacetazone in the treatment of tuberculosis in the state of Rio Grande do Sul (Brazil). .....(A) 243
Iberian Latin American Congress of Dermatology. .....(N) 119
Philippine Journal of Dermatology and Leprosy. Reyes-Javier, P. D. .....(N) 233

Dharmendra antigen,
assessment of. V. Attempts for purification of specific skin delayed hypersensitivity (DH) inducing antigen(s) from lepromin. Sengupta, U., *et al.* .....(A) 552
VI. Skin tests with fractionated nucleic acids. Sinha, S., *et al.* .....(A) 553

Diffuse lepromatous leprosy,
in Costa Rica. Castro-Coto, A. and Hidalgo-Hidalgo, H. .....(A) 388
Lucio phenomenon and . . . pure and primitive in a nonleprosy endemic area. Rea, T. H. .....(A) 392

Dimorphous leprosy,
Gilbert's syndrome (Criggler-Najjar type) with Hansen's disease of the . . . type. BANERJEE, K. .....(C) 509
transformation of lepromatous leprosy into. Terencio de las Aquas, J. and Rubio, F. C. .....(A) 546
with outbreaks of hansenic reaction and visceral lesions. .....(A) 246

Diphtheroids,
organisms (LDC) isolated in leprosy patients, Morphologic and biologic properties of. Delville, J., *et al.* .....(A) 554

Drug(s),
acidic anti-inflammatory, for treatment of leprous neuritis, Fundamental studies on the possibility of perineurotropic derivatives of. Tsutsumi, S., and Gidoh, M. .....(A) 590
antileprosy . . . on glycolytic processes in rats infected with *M. leprae*, influence of. Rezaev, A. A. .....(A) 245
—, three main, and their main metabolites in serum by high performance liquid chromatography, Determination of. Gidoh, M., *et al.* .....(A) 244
Bacterial growth kinetics of "M. lufu" in the presence and absence of various . . . alone and in combination. A model for the development of combined chemotherapy against *M. leprae*. SEYDEL, J. K. and WEMPE, E. G. .....(O) 20
— metabolism in patients with leprosy, *In vivo* and *in vitro*. Kumar, B., *et al.* .....(A) 538
multi-drug chemotherapy of leprosy and type 1 reaction, Short-term. PFALTZGRAFF, R. E. .....(C) 365

—, regimen pilot project at Oragadam Village (India). ....(N) 231
testing . . . activity against *Mycobacterium leprae*, Statistical analysis of results obtained by two methods for. SHEPARD, C. C. ....(O) 96
three . . . used most frequently for leprosy are dapsone, rifampin and clofazimine. ...(N) 235

Drug sensitivity,
— test strategy for atypical mycobacteria. Hejny, J. ....(A) 407
fixed genital drug eruption due to dapsone. Sinha, M. R. ....(A) 538

Electron microscopy,
— study of intra-cellular mycobacteria in experimental mouse tuberculosis. Kanai, K., *et al.* ....(A) 135
light and . . ., Immunological implications of necrotic, cellular and vascular changes in leprous neuritis. Dastur, D. K., *et al.* ....(A) 249
— — . . . , study, Blood staining of the cornea in Hansen's disease. Yoshimura, M. *et al.* ....(A) 248

Electrophoresis,
counter current, Demonstration of specific antibodies to *Mycobacterium leprae* by. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. ....(A) 396
electrophoretic pattern of proteins in lepromatous leprosy. Baji, P. S., *et al.* ....(A) 540

ELISA test(s) (enzyme-linked immunosorbent assay),
detection of anti-collagen type I and II antibodies by, results in rheumatoid arthritis, systemic lupus erythematosus and leprosy. Meghlaoui, A. ....(A) 250
Leprosy . . . antigen coating buffers and antigens: comparison of *M. leprae* whole organisms with other mycobacteria. Naka, S. O. and Douglas, J. T. ....(A) 600

Enzyme(s),
diverse hydrolic lysosomal, of murine peritoneal macrophages, effect of the infection with *Mycobacterium lepraemurium* on the level of. Phagocytosis in leprosy. 5. ROJAS-ESPINOSA, O., *et al.* ....(O) 306
serum, profile in tuberculoid leprosy. Bulakh, P. M., *et al.* ....(A) 541

Epidemiology,
clinical and epidemiological features of leprosy in two resettlement villages (Thailand). Vithayasai, V., *et al.* ....(A) 601
epidemiologic characteristics of leprosy. A study of the prevalence in the city of Santa Clara (Cuba). Gonzalez, A. N. and Apolinaire Pennin, J. J. ....(A) 260
—, evaluation of leprosy in New York City. Levis, W. R., *et al.* ....(A) 562
epidemiological aspects and implications of the disappearance of leprosy from Norway; some factors contributing to the decline. Irgens, L. M. ....(A) 261
—, information on leprosy in the Singu area of Upper Burma. Dominguez, V. M., *et al.* ....(A) 561
—, phenomenon, in Burma, of the skin test reagent LRA6; a cell-free extract from armadillo-derived *Mycobacterium leprae* Part 1. Leprosy patients. SHIELD, M. J., *et al.* ....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. ....(O) 446
—, —, on decreasing tendency of leprosy disease. Saikawa, K. ....(A) 563
—, situation in the Americas (Latin America). Motta, C. P. ....(A) 263
—, —, of leprosy in India. Christian, M. ....(A) 259
immunological tests as tools in . . . of leprosy, potential of. Kronvall, G. ....(A) 263
—, —, in epidemiological work, use of. ten Dam, H. G. and Sansarricq, H. ....(A) 266
leprosy epidemiometric model, torments and blessings of. Lechat, M. F. ....(A) 263
—, surveys in urban slums; possibilities for epidemiological investigations. Revankar, C. R., *et al.* ....(A) 404
lymphocyte transformation test in leprosy with special reference to its use in. Bjune, G. ....(A) 258
radioimmunoassay and other serological tests and their application to epidemiological work. Harboe, M. ....(A) 261
rapid socioeconomic development on the frequency of leprosy in a population, effect of. Saikawa, K. ....(A) 264

Erythema nodosum leprosum (ENL),
clinical activity of, Immune complexes in leprosy patients from an endemic and non-endemic area and a longitudinal study of the relationship between complement breakdown products and the. Valentijn, R. M., *et al.* ....(A) 399
lepromatous patients with, Pharmacologically active mediators of hypersensitivity reactions in the blood of. Saha, K. and Lahiri, S. C. ....(A) 252
precipitated by an imbalance of T lymphocytes, Hypothesis. Mshana, R. N. ....(A) 251
serum immunoglobulins and autoantibodies during and after. SHARMA, V. K., *et al.* ..(O) 159

Esterase,
acid non-specific . . . activity in leprosy patients, Investigation of T lymphocytes and. Qiang Nengxian, *et al.* ....(A) 251

Ethiopia,
All Africa Leprosy and Rehabilitation Training Centre (ALERT) international courses program 1982 ....(N) 226

Eye(s),
blood staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., *et al.* ....(A) 248
corneal changes in leprosy. A report of an autochthonous case. Farnarier, G., *et al.* ..(A) 542
ocular findings in leprosy: results of a survey in Green Pastures Leprosy Hospital (Nepal). Brandt, F., *et al.* ....(A) 128
—, —, —, leprous patients. A report of a survey in Malunga (Nepal). Brandt, F. and Malla, O. K. ....(A) 128

Fernandez reaction,
correlation between early . . . and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigens in three double-blind trials. Bechelli, L. M., *et al.* ...(A) 547

Filariasis,
bancroftian, in East Godavari district (A.P.) (India), General morbidity, leprosy, scabies and common cold in association with. Rao, C. K., *et al.* ....(A) 545
immunology of. ....(A) 135

Finger(s),
of leprosy patients having surgical removal of sublimus tendons. Reddy, N. R. and Kolumban, S. L. ....(A) 406
smear site selection with particular reference to the . . . . A study in 244 long-treated lepromatous patients. WARNDORFF-VAN DIEPEN, T. ....(O) 39
wrinkles in leprosy, Formation of. Sheskin, J., *et al.* ....(A) 129

Fluorescent leprosy antibody absorption (FLA-ABS) test,
diagnosis of leprosy by, Study on. Lee, H. and Kim, Y. ....(A) 397
— positive responders with special reference to their possible source of infection, Geographic distribution of. Immonoepidemiological studies on subclinical infection with *M. leprae*. III. Abe, M., *et al.* ....(A) 600
for early serodiagnosis of leprosy. Bharadwaj, V. P., *et al.* ....(A) 388
subclinical infection in leprosy; its detection and control by. Abe, M., *et al.* ....(A) 257

Foot pad(s),
infection in the hind . . . with *Mycobacterium marinum*, Response in distant lymph nodes of mice to. Mor, N., *et al.* ....(A) 559
inhibition of . . . multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* ....(A) 400
intraperitoneal vaccination against challenge in the . . . with *Mycobacterium marinum*. Protection of mice by. Ng, H., *et al.* ....(A) 560
mouse, Effect of deoxy fructo serotonin (DFS) on the multiplication of *M. leprae* in. Balakrishnan, S., *et al.* ....(A) 535
mouse . . . experiments with *M. leprae*, comparison of the skin scrape and skin biopsy methods in. Venkataramanaiah, H. N., *et al.* ....(A) 560

—, —, inoculation, brief review of experiences with short-term clinical trials monitored by. Shepard, C. C. ....(A) 245
response in the hind . . . and popliteal lymph node of C57Bl mice to infection with *Mycobacterium marinum*. Mor, N., *et al.* ....(A) 559

France,
Prix Paul Laviron ....(N) 514
Université Paris VII. Faculté de Médecine Lariboisière—Saint-Louis Certificat de Léprologie. ....(N) 375

Genetic(s),
— and non-. . . factors in leprosy, potential and limitations for analysis of. Population studies. Kidson, C. ....(A) 262
— polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from Thailand. Greiner, J., *et al.* ....(A) 130
genetically susceptible and resistant mice, disseminated leishmaniasis in; Experimental cutaneous leishmaniasis. Scott, P. A. and Farrell, J. P. ....(A) 409
Modern . . . Concepts and Techniques in the Study of Parasites. Michal, F. ....(B) 525

Genome,
— size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation: DNA isolated from *Mycobacterium leprae*. Imaeda, T., *et al.* ....(A) 400

Germany, Federal Republic of,
Deutsche Aussätzigen-Hilfswerke (DAHW) activities in leprosy. Kirchheimer, W. F. ..(N) 226
German Leprosy Relief Association's 25th anniversary. ....(N) 227
Hermann Kober receives Distinguished Service Cross from German government. ....(N) 513

Gilbert's syndrome,
(Criggler-Najjar type) with Hansen's disease of the dimorphous type. BANERJEE, K. ..(C) 509

Glomerulonephritis,
immunological bases of, in leprosy; a brief review. DATE, A. ....(E) 351
in leprosy. Ng, W. L., *et al.* ....(A) 391

Glycolysis,
influence of antileprosy drugs on glycolytic processes in rats infected with *M. leprae*. Rasaev, A. A. ....(A) 245

Guatemala,
Patrons for Action Against Leprosy of Guatemala elect new officers. Samayoa, J. M. ..(N) 381

Guinto, R. S.,
Notice of death ....(N) 516

H37Ra,
Mycobacterium tuberculosis . . . culture filtrate, Isolation and partial characterization of the most immunologically reactive antigen from. Reich, M., *et al.* ....(A) 567

Hand(s),
muscular wasting in the . . . from leprosy, Augmentation in. Harahap, M. ....(A) 267

Hansen's disease,
chemotaxis of monocytes in hanseniasis. AZULAY, R. D. ....(C) 215
College of Hansenology of the Endemic Countries founded. Azulay, R. D. and Motta, C. P. ....(N) 225
cornea in, Blood staining of the; a light- and electron-microscopic study. Yoshimura, M., *et al.* ....(A) 248
diagnosing, A test of wrinkle formation caused by soaking in warm water in. Sheskin, J., *et al.* ....(A) 247
dimorphous hanseniasis with outbreaks of hansenic reaction and visceral lesions. ....(A) 246
Gilbert's syndrome (Criggler-Najjar type) with, of the dimorphous type. BANERJEE, K. ..(C) 509
hepatic functions in relation to the clinical spectrum of hanseniasis. Pacin, A., *et al.* ..(A) 543
incidence of, in the state of Sao Paulo in 1978 (Brazil). Belda, W. and Lombardi, C. A. ....(A) 257

lactic dehydrogenase isoenzymes in the sera of hanseniasis patients. Garcia, R., *et al.* ..(A) 542
name changes reflect trends. ROTBERG, A. ....(C) 117
National Hansen's Disease Center, Audio-visual loan program at....(N) 516
—, —, —, —, International seminars on leprosy sponsored by American Leprosy Missions and. ....(N) 381
neuropathy in, Classification and treatment of. Charosky, C. B. ....(A) 267
1981–1982 Associção Brasileira de Hansenologia Board of Directors. Bechelli, L. M. ..(N) 122
Penikese Hospital; A Massachusetts hospital for the treatment of. Sabin, T. D. ....(A) 126
syphilis in . . . patients at Plaza Municipality (Cuba) during 1977. Serology to determine. Cardenas, Z. L., *et al.* ....(A) 541
—, in patients with. MURRAY, K. A....(O) 152

Hawaii,
immigration and leprosy in. WORTH, R. M. and BOMGAARS, M. R....(O) 335

Heiser Program, The
first five years. ....(N) 379
for research in leprosy; 1983 opportunities....(N) 380

Hepatitis,
— A and B virus markers (anti-HAV, HBsAf, HBsAb, HBeAg, HBeAb) in leprous patients. Ferlazzo, B., *et al.* ....(A) 390
— B virus infection in patients with leprosy; A serological study in leprosarium in Northern Nigeria. Fankule, Y. M. and Whittle, H. C. ....(A) 390

Histamine,
specific modulation of antigen stimulated human lymphocyte by. Nanda, N. K. and Nath, I. ....(A) 551

Histoid leprosy,
observations on ultrastructure of. LIU JIHE, *et al.* ....(O) 471
unusual presentation of. Singh, M., *et al.* ....(A) 393

Histology,
histologic profile in apparently normal skin of leprosy patients. Sakuntala, R., *et al.* ..(A) 552
of indeterminate leprosy. LIU TZE-CHUN, *et al.* ....(O) 172

Histopathology,
clinical and histopathological studies in classification of leprosy, Correlation of. Dubey, G. K., *et al.* ....(A) 389
histopathological change of leproma after BCG and levamisole injection in lepromatous leprosy patients, study on. Kim, D. ....(A) 396
—, features of leprosy lesions in the skin and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., *et al.* ....(A) 553
Kveim test in leprosy; a clinical and histopathological evaluation. Kaur, S., *et al.* ....(A) 246
Liver in leprosy. II. Histopathological changes. Robins, K., *et al.* ....(A) 398
nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., *et al.* ....(O) 58
of primary indeterminate leprosy. Liu Zijun, *et al.* ....(A) 550

HLA,
— and sporadic tuberculoid leprosy; a population study in Maharashtra (India). van Eden, W., *et al.* ....(A) 405
— D-identical siblings, Studies on the defect in cell-mediated immunity in lepromatous leprosy using. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* ....(A) 553
— linked control of the course of *M. leprae* infections. de Vries, R. R. P., *et al.*, ...(A) 260
— system, Analysis of the immunogenetic background of Japanese leprosy patients by. Izumi, S., *et al.* ....(A) 562
tuberculoid leprosy and . . . in Japanese. Miyanga, K., *et al.* ....(A) 404

Hypersensitivity,
age-specific tuberculin, The pattern of, in two groups of South African schoolchildren. Gatner, E. M. S. and Rubinstein, E. .....(A) 134
— and immunity in the spectrum of leprosy, The dissociation of. RIDLEY, D. S. .....(C) 363
DTH response to normal mice through infusion of splenic cells of such vaccinated mice, Inhibition of foot pad multiplication of *M. leprae* precursor coccoid organisms and passive transfer of. Bhide, M. B., *et al.* .....(A) 400
delayed . . . after BCG in preschool children in relation to their nutritional status (India). Seth, V., *et al.* .....(A) 268
—, —, (DH) inducing antigen(s) from lepromin, Attempts for purification of specific skin. Assessment of Dharmendra antigen. V. Sengupta, U., *et al.* .....(A) 552
delayed-type, Antigenic analysis of *M. leprae* in lepromins with reference to. Sengupta, U., *et al.* .....(A) 594
pharmacologically active mediators of . . . reactions in the blood of lepromatous patients with erythema nodosum leprosum. Kaha, K. and Lahiri, S. C. .....(A) 252
repeated delayed-type . . . reaction against *Mycobacterium lepraemurium* antigens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. .....(A) 363

IgA,
and IgM antibodies against *Mycobacterium leprae* in cord sera and in patients with leprosy; an indicator of intrauterine infection in leprosy. Melsom, R., *et al.* .....(A) 397
— nephropathy in leprosy (Letter to the Editor). Valles, M., *et al.* .....(A) 539

IgE,
circulating immunoglobulin levels in patients with pulmonary tuberculosis with special reference to. Gatner, E. M. S., *et al.* .....(A) 566
in leprosy. NUTI, M., *et al.* .....(C) 217

IgM,
IgA and . . . antibodies against *Mycobacterium leprae* in cord sera and in patients with leprosy; an indicator of intrauterine infection in leprosy. Melsom, R., *et al.* ..(A) 397

IMMLEP,
Annual report of . . . and THELEP, 1980–1981. .....(N) 233
IMMLEP Steering Committee meetings. .....(N) 516
testing of purified armadillo-derived *Mycobacterium leprae* in man. .....(N) 378

Immune complexes,
and complement in leprosy. Geniteau, M., *et al.* .....(A) 394
circulating, in normal blood donors of three races. Pudifin, D. J. and Duursma, J. ....(A) 251
in leprosy patients from an endemic and nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum. Valentijn, R. M., *et al.* .....(A) 399
in the spectrum of tuberculosis. Brostoff, J., *et al.* .....(A) 134

Immune responses,
and immunostimulation in tuberculosis therapy. Gatner, E. M. S. and Anderson, R. ..(A) 566
high immune and low resistance granulomas in leprosy, immunoperoxidase study of immunological factors in. Ridley, M. J. and Russell, D. .....(A) 551
humoral, Subcutaneous amyloid deposits and; a family study of leprosy. WANGEL, A. G., *et al.* .....(O) 47
immune status in pulmonary tuberculosis patients. Mirza, Z. .....(A) 567
strain difference of, in mice infected with *Mycobacterium lepraemurium*. Hirooka, Y., *et al.* .....(A) 558

Immunity,
cell-mediated, effect of body temperature and . . . on the growth of *Mycobacterium marinum* and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* .....(A) 556
—, in lepromatous leprosy using HLA-D-identical siblings, Studies on the defect in. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* .....(A) 553
—, of guinea pigs examined by rabbit red blood cell rosette formation method, On the immunodepressive effect of rifampicin (RFP) on. Gidoh, M. and Tsutsumi, S. ..(A) 386

cell-mediated and humoral, consequence of alterations of . . . during pregnancy and lactation. Pregnancy and leprosy. DUNCAN, M. E., *et al.* .....(O) 425
humoral, in leprosy: immunoglobulin G and M antibody responses to *Mycobacterium leprae* in relation to various disease patterns. Touw, J., *et al.* .....(A) 553
hypersensitivity and . . . in the spectrum of leprosy, dissociation of. RIDLEY, D. S. ....(C) 363
macrophages and protective, in *Mycobacterium lepraemurium* infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. .....(A) 560
specific, in protecting against leprosy, relative importance of. Bryceson, A. .....(A) 258

Immunoglobulin(s),
circulating . . . levels in patients with pulmonary tuberculosis with special reference to IgE. Gatner, E. M. S., *et al.* .....(A) 566
— class specific antibodies in *M. leprae* in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Melsom, R., *et al.* .....(A) 397
— G and M antibody responses to *Mycobacterium leprae* in relation to various disease patterns. Humoral immunity in leprosy. Touw, J., *et al.* .....(A) 553
salivary, in leprosy. GUPTA, S. C., *et al.* .....(C) 219
serum, and autoantibodies during and after erythema nodosum leprosum (ENL). SHARMA, V. K., *et al.* .....(O) 159

Immunology,
leprosy. Cabrini, J. M., *et al.* .....(A) 249
of filariasis. .....(A) 135
of leprosy, mycobacteriologist's view of. Stanford, J. L. .....(A) 398
—, speculations on the leprosy spectrum. Sasonetti, P. and Lagrange, P. H. .....(A) 131

Immunoperoxidase,
— study of immunological factors in high immune and low resistance granulomas in leprosy. Ridley, M. J. and Russell, D. .....(A) 551
—, —, —, —, in skin lesions across the spectrum of leprosy. RIDLEY, M. J., *et al.* ...(O) 11

Immunotherapy,
of leprosy. Leon, A. P. .....(A) 130
with a mixture of *Mycobacterium leprae* and BCG in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., *et al.* .....(O) 415

Indeterminate leprosy,
a valid clinical concept. BROWNE, S. G. .....(C) 221
histology of. LIU TZE-CHUN, *et al.* .....(O) 172
histopathology of primary. Liu Zijun, *et al.* .....(A) 550
how . . . got its name. Arnold, H. L. .....(A) 243
reply to Dr. Browne's Letter to the Editor. PETTIT, JOHN H. S. .....(C) 224
specific skin test responses in children of patients with . . . tuberculoid leprosy, and lepromatous leprosy. Gimenez, M. and Morini, J. C. .....(A) 395

India,
age at onset of leprosy (analytic data from northern India). Sehgal, V. N., *et al.* .....(A) 563
Anti-leprosy Day 1982. .....(N) 236
bancroftian filariasis in East Godavari district (A.P.), General morbidity, leprosy, scabies and common cold in association with. Rao, C. K., *et al.* .....(A) 545
BCG in preschool children, Delayed hypersensitivity after, in relation to their nutritional status. Seth, V., *et al.* .....(A) 268
Birla Smarak Kosh award for Professor Talwar. .....(N) 230
Bombay, ILO/DANIDA Asian regional seminar on vocational rehabilitation. .....(N) 227
Bombay Leprosy Project; Report of Activities 1976–1981. .....(N) 514
Dr. B. C. Roy National Award to Dr. A. J. Selvapandjan. .....(N) 231
epidemiological situation of leprosy in. Christian, M. .....(A) 259
Green Pastures Leprosy Hospital—Nepal, Ocular findings in leprosy: Results of a survey in. Brandt, F., *et al.* .....(A) 128
HLA and sporadic tuberculoid leprosy: a population study in Maharashtra. van Eden, W., *et al.* .....(A) 405

ICMR awards for 17 scientists. ....(N) 230
illness and service utilization behaviours of leprosy patients. Kumar, A. and Anbalagan, M. ....(A) 564
immunoepidemiological studies on subclinical infection in leprosy in household contacts in; a preliminary report. Bharadwaj, V. P., *et al.* ....(A) 600
Indian Association of Leprologists, new officers of. ....(N) 124
Indian Council of Medical Research, *Annual Report of the Director-General 1980–81.* Ramalingaswami, V. ....(B) 527
leprosy among urban and rural schoolchildren of Andhra Pradesh, study of. Rao, P. S. S., *et al.* ....(A) 563
—, cases in the Gandhi Kusth Ashram, Jodhpur (Rajasthan), sociological study of. Vyas, G. K., *et al.* ....(A) 566
—, control: renewed effort by the government of. Saxena, M. L. and Johnsen, D. O. ..(N) 375
Malunga (Nepal), report of a survey in. Ocular findings in leprous patients. Brandt, F. and Malla, O. K. ....(A) 128
Nepal Leprosy Relief Association. Shrestha, K. B. ....(N) 123
Oragadam Village, Multi-drug regiment pilot project. ....(N) 231
Padma Bhushan honor to Dr. J. M. Mehta. ....(N) 230
Prime Minister Gandhi addresses the American Association for the Advancement of Science. ....(N) 522
prizes for medical students. ....(N) 236
Tamil Nadu, Leprosy in. ....(A) 538
XII International Leprosy Congress. ....(N) 515
Urban Leprosy Control. ....(B) 383
Workshop of National Leprosy Control Programme of Varansi Region. ....(N) 230

Indonesia,
leprosy control in Surabaya. Soendijojo, A., *et al.* ....(A) 405

Inoculation,
animal, *In vitro* cultivation of *Mycobacterium lepraemurium* and its identification by. Ishaque, M. ....(A) 132
experimental animals inoculated with *M. leprae,* comparative study of the nerve lesions of. Nishiura, M. and Fukunishi, Y. ....(A) 589
intra-upper lip . . . method, NFS/N nude mouse as a new model using. The nude mouse as an experimental lepromatous model (continued). Nakamura, K. and Yogi, Y. ....(A) 585
mouse food pad, brief review of experiences with short-term clinical trials monitored by. Shepard, C. C. ....(A) 245
of *Mycobacterium leprae* into the 'rhino mouse'. Kohsaka, K., *et al.* ....(A) 583

INTERNATIONAL JOURNAL OF LEPROSY (IJL),
German Leprosy Relief Association congratulates. Kober, H. ....(N) 513
1981 JOURNAL; a continuing perspective. HASTINGS, R. C. ....(E) 102
requests news from national leprosy organizations. Lechat, M. F. ....(N) 122
reviewers, list of ....(—) 604
statement of financial condition ....(—) 410
statement of ownership, management and circulation ....(—) 618

International Leprosy Association (ILA),
fiftieth renewal of membership in . . . by Dr. S. Takashima. ....(N) 376
organization and membership ....(—) 605
International Leprosy Congress, XII,
first notice. Brown, S. G. ....(N) 120
revised dates and program ....(N) 515
Isoniazid (INH),
combination of . . . prothionamide and dapsone against *Mycobacterium leprae* and some other mycobacteria, Activity of. Pattyn, S. R., *et al.* ....(A) 387
in the treatment of experimental mouse tuberculosis, role of low dosage prothionamide with and without 4,4′-diaminodiphenyl sulphone for use with. Grosset, J., *et al.* ..(A) 407

resistance to rifampicin and . . . in strains of *Mycobacterium tuberculosis*. Siddiqi, S. H., *et al.* .....(A) 409

Italy,
Leonard Wood Memorial Scientific Symposium, Bellagio, 2–4 June 1982. .....(N) 521

Japan,
Dr. S. Takashima, Fiftieth renewal of membership in ILA. .....(N) 376
Japanese leprosy patients, Analysis of the immunogenetic background of, by the HLA system. Izumi, S., *et al.* .....(A) 562
Sasakawa Memorial Health Foundation (SMHF) reference and health learning materials. .....(N) 231
tuberculoid leprosy and HLA in. Miyanga, K., *et al.* .....(A) 404
U.S.-. . . Cooperative Medical Science Program, Seventeenth Joint Leprosy Research Conference, Sendai, Japan, 25–27 July 1982. .....(—) 569

Karat, Aaron Benedict Abiel,
obituary. Brand, P. W. .....(Ob) 359

Kidney(s)
IgA nephropathy in leprosy. (Letter to the Editor). Valles, M., *et al.* .....(A) 539

Kinetics,
bacterial growth, of "M. lufu" in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against *M. leprae*. SEYDEL, J. K. and WEMPE, E. G. .....(O) 20
pre-S-phase cell cycle, of mitogen-stimulated normal human lymphocytes, Serum inhibitory factor in lepromatous leprosy; its effect on. Potts, R. C., *et al.* .....(A) 251

Korea,
DDS-resistant leprosy in. Kim, D. .....(A) 386
Miss Grace Bennett retires from The Leprosy Mission (TLM) in. .....(N) 376

Kveim test,
in leprosy; a clinical and histopathological evaluation. Kaur, S., *et al.* .....(A) 246

Lactation,
breast secretion of lactating mothers with lepromatous leprosy, Decreased cellular and humoral anti-infective factors in. Saha, K., *et al.* .....(A) 252
neuritis in pregnancy and. DUNCAN, M. E. and PEARSON, J. M. H. .....(O) 31
pregnancy and, consequence of alterations of cell-mediated and humoral immunity during: pregnancy and leprosy. DUNCAN, M. E., *et al.* .....(O) 425

Lactic/Lactate,
blood . . . and pyruvic acids in leprosy, effect of dapsone on. SINHA, S. N., *et al.* ...(O) 468
— dehydrogenase in sera of patients with leprosy, anomalous isoenzymes of. Saoji, A. M. and Kelkar, S. S. .....(A) 557
—, —, isoenzymes in the sera of hanseniasis patients. Garcia, R., *et al.* .....(A) 542
serum . . . dehydrogenase isoenzyme patterns in leprosy, Qualitative studies of. Saoji, A. M. and Kelkar, S. S. .....(A) 247

Lamprene®,
ILEP information on side-effects from clofazimine. .....(N) 233

Lara, Casmiro B.,
Obituary. Jose, F. A., Jr. .....(Ob) 213

Latin America,
epidemiological situation in the Americas. Motta, C. P. .....(A) 263
Iberian Latin American Congress of Dermatology .....(N) 119

Leishmaniasis,
experimental cutaneous, Disseminated . . . in genetically susceptible and resistant mice. Scott, P. A. and Farrell, J. P. .....(A) 409

Leonard Wood Memorial,
— Laboratory/Cebu/Philippines, Third Standardization Workshop for Joint Chemotherapy Trials. Reich, C. V. .....(N) 124
— Scientific Symposium, Bellagio, Italy, 2–4 June 1982. .....(N) 521
Leprosy Scientific Memoranda to resume in fall 1982. .....(N) 522

Leproma,
histoid, Observations on ultrastructure of. LIU JIHE, *et al.* .....(O) 471
histopathological change of, after BCG and levamisole injection in lepromatous leprosy patients, study on. Kim, D. .....(A) 396
Mycobacterial strains adapted to cultures separated from human, Identifying characteristics vis-a-vis *Mycobacterium leprae*. Coudert, J., *et al.* .....(A) 554
rat or mice, are not the aetiologic agents of murine leprosy, Mycobacteria of *Mycobacterium scrofulaceum* type isolated from. Ishaque, M. .....(A) 555

Lepromatous leprosy,
active, Reversion of the downhill course of, by repeated transfusions of fresh blood; donated by healthy but lepromin positive patients. Saha, K., *et al.* .....(A) 552
BCG and levamisole injection in . . . patients, study on histopathological change of leproma after. Kim, D. .....(A) 396
blood of . . . patients with erythema nodosum leprosum, Pharmacologically active mediators of hypersensitivity reactions in. Saha, K. and Lahiri, S. C. .....(A) 252
breast secretions of lactating mothers with . . ., Decreased cellular and humoral antiinfective factors in. Saha, K., *et al.* .....(A) 252
cell-mediated immunity in, Studies on the defect in, using HLA-D-identical siblings. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* .....(A) 553
children of patients with indeterminate leprosy, tuberculoid leprosy, and . . ., Specific skin test responses in. Gimenez, M. and Morini, J. C. .....(A) 395
class specific anti-*Mycobacterium leprae* antibody assay in . . . (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* .....(O) 271
clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with, Effects of. Van Rensburg, C. E., *et al.* ...(A) 539
dermal infiltrate in, morphology of bacilli at different levels of. GIRDHAR, B. K. and MCDOUGALL, A. C. .....(O) 477
diffuse, in Costa Rica. Castro-Coto, A. and Hidalgo-Hidalgo, H. .....(A) 388
human testis in patients with, Immunoreactivity *in vitro* to. Wall, J. R. and Walters, B. A. J. .....(A) 255
In vitro lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. Effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* .....(O) 455
leucocytes from . . . patients with hapten modified *M. leprae*, Improved leucocyte migration inhibition response of. Fotedar, A., *et al.* .....(A) 547
Lucio phenomenon in a case of lepromatous paucinodular leprosy. Peyri, L., *et al.* ...(A) 544
lymphocyte transformation test (LTT) by phytohemagglutinin, lepromin and *M. leprae* in . . . patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* .....(A) 548
M. leprae isolated from the lymph of a . . . patient by means of the freeze-fracture technique, Studies on. Sanabria Negrin, J. G., *et al.* .....(A) 556
mouse as an experimental . . . model, hereditarily athymic asplenic (LASAT), (continued): role of the spleen in the formation of the lepromatoid lesions. Nakamura, K. and Yogi, Y. .....(A) 586
—, —, —, —, nude (continued): the NFS/N nude mouse as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. .....(A) 585
natural resistance against tetanus, in patients with. Saha, K., *et al.* .....(A) 392
nerve abscess in. Malaviya, G. N., *et al.* .....(A) 543
nose in, bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., *et al.* .....(O) 58
ocular lesions in. Chovet, M., *et al.* .....(A) 128
proteins in, Electrophoretic pattern of. Baji, P. S., *et al.* .....(A) 540

rat as an experimental . . . model, nude (continued): effects of carrageenans, splenectomy, and treatment with thymus cells. Nakamura, K. and Yogi, Y. .....(A) 587
rifampicin, Once-monthly, plus daily dapsone in initial treatment of. Yawalkar, S. J., *et al.* .....(A) 540
serological and immunohistological studies on. Kano, K., *et al.* .....(A) 550
serum inhibitory factor in, its effect of the pre-S-phase cell cycle kinetics of mitogen-stimulated normal human lymphocytes. Potts, R. C., *et al.* .....(A) 251
small bowel in, Structure and function of. KUMAR, N., *et al.* .....(O) 148

Lepromin,
antigenic analysis of *M. leprae* in . . . with reference to the delayed type of hypersensitivity. Sengupta, U., *et al.* .....(A) 594
cytoplasmic mycobacterial antigens on the late reactivity to, Double blind trial on the effect of certain soluble. HADDAD, N., *et al.* .....(O) 325
healthy but . . . positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated transfusions of fresh blood donated by. Saha, K., *et al.* ..(A) 552
integral . . . and . . . treated with ultrasound, study comparing the interdermal reactions following, in normal individuals. Karazawa, E. H., *et al.* .....(A) 550
— test, Type 1 lepra reaction induced by; a case report. Dong Li-Wen, *et al.* .....(A) 541
lymphocyte transformation test (LTT) by phytohemagglutinin, . . . and *M. leprae* in lepromatous leprosy patients, negatives and positives: prognostic value compared with that of . . . . Guimaraes Pagnano, P. M., *et al.* .....(A) 548
normal bacillary, Cutaneous response to, incubated with sera from patients with distinct clinical forms of leprosy. Corona, C. J. J., *et al.* .....(A) 249
post . . . scar, Studies on. Tarabini-Castellani, G., *et al.* .....(A) 253
purification of specific skin delayed hypersensitivity (DH) inducing antigens from . . ., Attempts for. Assessment of Dharmendra antigen. V. Sengupta, U., *et al.* ...(A) 552
skin test response to *M. leprae* precursor coccoid organisms in a high leprosy endemic area as compared to. Chatterjee, B. R. .....(A) 400
tissue response to, index of susceptibility of the armadillo to *M. leprae* infection; a preliminary report. JOB, C. K., *et al.* .....(O) 177
whole human and armadillo . . . in 50 leprosy patients, comparative study. Mitsuda reaction. Zambrano, M. T., *et al.* .....(A) 129

Leprosy,
Abu Ali Ibn-Sina (Avicenna) on. Abdullaev, A. H. and Sharafiddinov, T. A. .....(A) 534
An Atlas of Leprosy. Guinto, R. S., *et al.* .....(B) 239
information sources of . . . with particular reference to developing countries. Dorrington, L. .....(A) 385
—. Binford, C. H., *et al.* .....(A) 385
—; a disease of the heart. Crawshaw, R. .....(A) 534
— a zoonosis. Walsh, G. P., *et al.* .....(A) 267
quality of service to . . . patients, Factors influencing. MCDOUGALL, A. C. .....(E) 355

Lesions,
dermal, of leprosy, *in situ* characteristics of mononuclear cell infiltrates in. GUPTA, S. K., *et al.* .....(O) 297
histopathological features of leprosy . . . in the skin and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., *et al.* .....(A) 553
human and murine leprosy, egg-yolk reaction produced by, and its cultural significance on primary isolation. Koseki, Y., *et al.* .....(A) 577
—, leprosy, Base compositions and homologies of deoxyribonucleic acids of corynebacteria isolated from, and of related microorganisms. Danhaive, P., *et al.* .....(A) 256
—, —, Chemical identification of some cell wall components of microorganisms isolated from. Janczura, E., *et al.* .....(A) 401
—, —, skin, Immunohistopathologic study of β-glucuronidase and lysozyme in. Matsuo, E., *et al.* .....(A) 599
hypo-pigmented, in children, study of. Dutta, R. K. and Murthy, N. .....(A) 389
lepromatoid, role of the spleen in the formation of the. Hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. .....(A) 586

nerve, of experimental animals inoculated with *M. leprae*, Comparative study of. Nishiura, M. and Fukunishi, Y. ....(A) 589
ocular, in lepromatous leprosy. Chovet, M., *et al.* ....(A) 128
—, in leprosy. Reddy, S. C., *et al.* ....(A) 247
orofacial, of leprosy, Clinical evaluation of. Prabhu, S. R. and Daftary, D. K. ....(A) 545
skin, across the spectrum of leprosy, immunoperoxidase study of immunological factors in. RIDLEY, M. J., *et al.* ....(O) 11
ultrastructures of cells in . . . of lepromatous and tuberculoid leprosy. Liu Zijun, *et al.* ..(A) 551
visceral, Dimorphous hanseniasis with outbreaks of hansenic reaction and. ....(A) 246

Leukocytes,
improved leucocyte migration inhibition response of, from lepromatous leprosy patients with hapten modified *M. leprae*. Fotedar, A., *et al.* ....(A) 547
leukocytoclastic vasculitis. Mackel, S. E. and Jordan, R. E. ....(A) 407
polymorphonuclear . . . (PMN) chemotaxis, Thalidomide does not affect. Miyachi, Y. and Ozaki, M. ....(A) 387

Levamisole,
BCG and . . . injection in lepromatous leprosy patients, study on histopathological change of leproma after. Kim, D. ....(A) 396

Lipid(s),
— composition of *Mycobacterium phlei*, Effect of growth temperature and exogenous fatty acids on. Taneja, R., *et al.* ....(A) 567
lipidic constituents of *Mycobacterium leprae* isolated from experimentally infected armadillo. Asselineau, C., *et al.* ....(A) 131
of *Mycobacterium gordonae* in comparison with those of *M. leprae* and of some other scotochromogenic mycobacteria, Studies on. Daffe, M., *et al.* ....(A) 400

Liposome,
stimulation of growth of *Mycobacterium lepraemurium* in cell-free liquid medium by aspartic acid, sucrose, . . . , thymidine, and deoxyuridine (NDLASU medium). Nakamura, M. ....(A) 578

Liver(s),
antitoxic function of, in patients with leprosy, Radioisotope detection of. Kharatyan, A. M. and Kenzhebaev, A. Y. ....(A) 396
armadillo, infected with *Mycobacterium leprae*, Isolation of fastidiously growing mycobacteria from. PORTAELS, F. and PATTYN, S. R. ....(C) 370
—, Superoxide dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with. Wheeler, P. R. and Gregory, D. ....(A) 557
in leprosy. II. Histopathological changes. Robins, K., *et al.* ....(A) 398

Lucio leprosy,
Lucio phenomenon. Compa, F. V., *et al.* ....(A) 389
—, —, and diffuse lepromatous leprosy pure and primitive in a nonleprosy endemic area. Rea, T. H. ....(A) 392
—, —, in a case of lepromatous paucinodular leprosy. Peyri, L., *et al.* ....(A) 544
Lucio's leprosy. Compa, F. V., *et al.* ....(A) 389
spectrum of the necrotizing lepra reactions. (Allergic cutaneous vasculitis; Lucio phenomenon.) A proposed intermediate lepra reaction. Peyri, L., *et al.* ....(A) 545

Lupus vulgaris,
BCG vaccine-induced. Izumi, A. K. and Matsunaga, J. ....(A) 407

Lymph node(s),
distant, of mice, Response in, to infection in the hind foot pad with *Mycobacterium marinum*. Mor, N., *et al.* ....(A) 559
immunologic functions of, in leprosy, Preliminary study on. Gu Zhijie, *et al.* ....(A) 548
popliteal, Response in the hind foot pad and, of C57Bl mice to infection with *Mycobacterium marinum*. Mor, N., *et al.* ....(A) 559

Lymphocyte(s),
antigen stimulated human . . . by histamine, Specific modulation of. Nanda, N. K. and Nath, I. .....(A) 551
in vitro . . . stimulation in patients with lepromatous and borderline tuberculoid leprosy. Effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* .....(O) 455
—, —, —, stimulation using a purified antigen of *M. leprae* and tuberculin PPD. Closs, O. and Reitan, L. J. .....(A) 259
—, —, stimulation of . . . in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Closs, O., *et al.* .....(A) 547
macrophages versus . . . in leprosy. BEIGUELMAN, B. .....(E) 501
mitogen-stimulated human, Serum inhibitory factor in lepromatous leprosy; its effect on the pre-S-phase cell cycle, kinetics of. Potts, R. C., *et al.* .....(A) 251
neutrophil and . . . functions in normal individuals and patients with lepromatous leprosy, Effects of clofazimine alone or combined with dapsone on. Van Rensburg, C. E., *et al.* .....(A) 539
peripheral blood, Prostaglandin-dependent regulation of the *in vitro* proliferative response to mycobacterial antigens of, from normal donors and from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* .....(A) 129
—, —, T and B . . . in leprosy, study of. Hee Chul Eun, *et al.* .....(A) 549
PHA induced blastoid transformation of . . . in leprosy contacts. Hardas, U. D. and Jalgaonkar, S. V. .....(A) 536
phytohaemagglutinin (PHA)-induced . . . transformation, *in vitro* effect of DDS on. Ghei, S. K., *et al.* .....(A) 395
T . . ., Absence of circulating suppressor cells and evidence that the defect is in, rather than the monocyte population. Studies on the defect in cell-mediated immunity in lepromatous leprosy using HLA-D-identical siblings. Stoner, G. L., *et al.* .....(A) 553
—, —, and acid non-specific esterase activity in leprosy patients, Investigation of. Qiang Nengxian, *et al.* .....(A) 251
—, —, Hypothesis: erythema nodosum leprosum is precipitated by an imbalance of. Mshana, R. N. .....(A) 251
—, —, subsets in leprosy granulomas, *In situ* characterization of. MODLIN, R. L., *et al.* .....(C) 361
thymus dependent, in leprosy. I. T . . . subpopulations defined by monoclonal antibodies. MSHANA, R. N., *et al.* .....(O) 291
transformation of, from normal individuals, *in vitro* and *in vivo* effects of clofazimine on the motility of neutrophils and. Gatner, E. M. S., *et al.* .....(A) 386

Lymphocyte transformation test (LTT),
by phytohemagglutinin, lepromin and *M. leprae* in lepromatous leprosy patients, negatives and positives; prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* .....(A) 548
in leprosy with special reference to its use in epidemiology. Bjune, G. .....(A) 258

Lysozyme,
β-glucuronidase and . . . in human leprosy skin lesions, Immunohistopathologic study of. Matsuo, E., *et al.* .....(A) 599
serum . . . (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* .....(A) 246
tear, in lepromatous leprosy. SEN, D. K. and SARIN, G. S. .....(O) 322

Macrophage(s),
and protective immunity in *Mycobacterium lepraemurium* infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. .....(A) 560
differentiated human, Incorporation of ^{3}H-thymidine in *Mycobacterium leprae* within. Prasad, H. K. and Nath, I. .....(A) 132
human, effect of *M. leprae* on phagosome-lysosome fusion in. Scollard, D. M. and Gardner, I. D. .....(A) 596

— culture method, Rapid, for detection of dapsone-resistant *Mycobacterium leprae*. Nath, I., *et al.* .....(A) 244
— cultures, *In vitro* growth of *Mycobacterium lepraemurium* under the influence of. Matsuo, Y. and Tatsukawa, H. .....(A) 401
murine peritoneal, effect of the infection with *Mycobacterium lepraemurium* on the level of diverse hydrolic lysosomal enzymes of. Phagocytosis in leprosy. 5. Rojas-Espinosa, O., *et al.* .....(O) 306
of nude mice, Ultrastructural features of the multiplication of human and murine leprosy bacilli in. Fukunishi, Y., *et al.* .....(O) 68
versus lymphocytes in leprosy. Beiguelman, B. .....(E) 501

Macular leprosy,
macular indeterminate form of leprosy. Strobel, M., *et al.* .....(A) 393

Madagascar,
ocular disease in leprosy in, Contribution to the study of. Andriantsoa-Rasoavelonoro, V., *et al.* .....(A) 127

Malaysia,
Kuala Lumpur, Fourth International Workshop on Leprosy Control in Asia, site of. Lechat, M. F. .....(N) 515
—, —, meeting on social and economic aspects of leprosy (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases) .....(N) 376

Mali,
Paraclinical study of onchocerciasis in a leprous and nonleprous population. Penchier, L., *et al.*, ...(A) 392

Metabolism,
antileprosy drugs and their main metabolites in serum by high performance liquid chromatography, Determination of three main. Gidoh, M., *et al.* .....(A) 244
cholesterol, Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a further probe into. Kannan, K. B., *et al.* .....(A) 542
differential . . . of fatty acid by mycobacteria, Radiometric measurement of. Camargo, E. E., *et al.* .....(O) 200
— activity of purified suspensions of *Mycobacterium leprae*, Preliminary studies of. Khanolkar, S. R. .....(A) 401
new urinary metabolite of clofazimine in leprosy patients. Feng, P. C. C., *et al.* .....(A) 536
of clofazimine in leprosy patients. Feng, P. C. C., *et al.* .....(A) 385

Mexico,
endemic behavior of leprosy in, during 1980. .....(A) 403
Mexican Association of Action Against Leprosy, annual meeting of. Latapi, F. .....(N) 516
Mexican Leprosy Society meeting in Zacatecas. .....(N) 516

Mice,
bacillary multiplication in C3H . . ., Repeated delayed-type hypersensitivity reaction against *Mycobacterium lepraemurium* antigens at the infection site do not affect. Løvik, M. and Closs, O. .....(A) 397
dapsone in protein deficiency, Disposition of; an experimental study in . . . Venkatesan, K., *et al.* .....(A) 540
disseminated leishmaniasis in genetically susceptible and resistant . . ., Experimental cutaneous leishmaniasis. Scott, P. A. and Farrell, J. P. .....(A) 409
distant lymph nodes of, Response in, to infection in the hind foot pad with *Mycobacterium marinum*. Mor, N., *et al.* .....(A) 559
experimental infection with *Mycobacterium lepraemurium* in the CBA/J . . . . Effects of preimmunization on the evolution of the disease. Corona, C. J. J., *et al.* .....(A) 402
hairless, (*Mus musculus*), Experimental leprosy with *Mycobacterium lepraemurium* in. Packchanian, E., *et al.* .....(A) 560
hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous leprosy model (continued): role of the spleen in the formation of the lepromatoid lesions. Nakamura, K. and Yogi, Y. .....(A) 586
hind foot pad and popliteal lymph node of C57Bl . . . to infection with *Mycobacterium marinum*, Response in. Mor, N., *et al.* .....(A) 559

immune responses in, infected with *Mycobacterium lepraemurium*, Strain difference of. Hirooka, Y., *et al.* .....(A) 558
inhibition of foot pad multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal . . . through infusion of splenic cells of such vaccinated . . . . Bhide, M. B., *et al.* .....(A) 400
intraperitoneal vaccination against challenge in the foot pad with *Mycobacterium marinum*, Protection of . . . by. Ng, H., *et al.* .....(A) 560
M. leprae in mouse foot pad, effect of deoxy fructo serotonin (DFS) on the multiplication of. Balakrishnan, S., *et al.* .....(A) 535
— infected with *Mycobacterium lepraemurium*, Antibacterial resistance in. Patel, P. J. .....(A) 133
mouse foot pad experiments with *M. leprae*, comparison of the skin scrape and skin biopsy methods in. Venkataramanaiah, H. N., *et al.* .....(A) 560
—, —, —, inoculation, experiences with short-term clinical trials monitored by, A brief review of. Shepard, C. C. .....(A) 245
—, tuberculosis, experimental, electron microscopy study of intra-cellular mycobacteria in. Kanai, K., *et al.* .....(A) 135
—, —, treatment of experimental, role of low dosage prothionamide with and without 4,4′-diaminodiphenyl sulphone for use with isoniazid in. Grosset, J., *et al.* .....(A) 407
murine leprosy in C3H . . . vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with *Mycobacterium bovis* (BCG), Lack of a sustained protection against. TURCOTTE, R. and LEMIEUX, S. .....(O) 494
mycobacteria of *Mycobacterium scrofulaceum* type isolated from rat or . . . lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. .....(A) 555
Mycobacterium avium of C3H/H3 . . ., Susceptibility to. Kawaguchi, Y., *et al.* .....(A) 558
—, —, of various inbred strains of, Susceptibility to. I. On the cases with intraperitoneal infection. Tanemura, M. .....(A) 402
II. On the cases with subcutaneous infection. Tanemura, M. .....(A) 402
—, *leprae* infection in, Effects of *Propionibacterium acnes* treatment on the course of. Krahenbuhl, J. L., *et al.* .....(A) 558
—, *lepraemurium* infection in, lack of correlation between antigen-specific reactions and resistance to. Curtis, J., *et al.* .....(A) 256
—, *marinum* and *Mycobacterium leprae* in, effect of body temperature and cell-mediated immunity on the growth of. Lancaster, R. D., *et al.* .....(A) 556
pathogenicity in, and the ability of *M. lepraemurium* to grow in tissue culture cells, relationship between. Nomaguchi, H., *et al.* .....(A) 578
'resistant' (C56Bl) and a 'susceptible' (BALB/c) mouse strain, Macrophages and protective immunity in *Mycobacterium lepraemurium* infections in. Preston, P. M. ...(A) 560
rhino mouse, Inoculation of *Mycobacterium leprae* into. Kohsaka, K., *et al.* .....(A) 583
sciatic nerve compound action potential *in vitro* in normal and *M. leprae* infected . . ., A study of. Vidyasagar, P. B., *et al.* .....(A) 401
—, nerves in experimental, Nerve damage in leprosy; a teased fibre study of. Bhat, R. and Vaidya, M. C. .....(A) 557
survival of BALB/c . . . after intravenous infection with *Mycobacterium marinum*. Ng, H., *et al.* .....(A) 560
various mouse strains infected with a large or small dose of murine leprosy bacilli, Mitogen-induced DNA synthesis in. Yamaura, N., *et al.* .....(A) 399

Mice, nude,
as an experimental lepromatous model (continued): the NFS/N . . . as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. .....(A) 585
in studies of leprosy. Colston, M. J. and Kohsaka, K. .....(A) 557
leprosy chemotherapy in, study of. Effect of dapsone (DDS) on . . . experimentally infected with *Mycobacterium leprae*. Yoneda, K., *et al.* .....(A) 582
macrophages of, Ultrastructural features of the multiplication of human and murine leprosy bacilli in. FUKUNISHI, Y., *et al.* .....(O) 68

Mitsuda reaction,
early (Fernandez) and late . . . in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials, Correlation between. Bechelli, L. M., *et al.* .....(A) 547
Mitsuda-negative contacts, Immunotherapy with a mixture of *Mycobacterium leprae* and BCG in different forms of leprosy and in. CONVIT, J., *et al.* .....(O) 415

—. Comparative study with whole human and armadillo lepromin in 50 leprosy patients. Zambrano, M. T., *et al.* .....(A) 129

Monkeys,
multibacillary leprosy in unaltered hosts, with emphasis on armadillos and . . . Meyers, W. M., *et al.* .....(A) 584

Monocytes,
chemotaxis of, in hanseniasis. AZULAY, R. D. .....(C) 215

Morphology,
morphologic and biologic properties of diphtheroid organisms (LDC) isolated in leprosy patients. Delville, J., *et al.* .....(A) 554
of bacilli at different levels of the dermal infiltrate in lepromatous leprosy. GIRDHAR, B. K. and MCDOUGALL, A. C. .....(O) 477

Muramyl dipeptide,
absence of antibodies to, in patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..(A) 394

Murine leprosy,
aetiologic agents of, Mycobacteria of *Mycobacterium scrofulaceum* type isolated from rat or mice lepromata are not the. Ishaque, M. .....(A) 555
experimental, Suppressor cells in. Akiyama, T., *et al.* .....(A) 595
human and . . . bacilli in macrophages of nude mice, Ultrastructural features of the multiplication of. FUKUNISHI, Y. *et al.* .....(O) 68
—, —, —, lesions, egg-yolk reaction produced by, and its cultural significance on primary isolation. Koseki, Y., *et al.* .....(A) 577
— bacilli, Mitogen-induced DNA synthesis in various mouse strains infected with a large or small dose of. Yamaura, N., *et al.* .....(A) 399
—, —, phospholipid deacylating activities in. Kashiwabara, Y. and Nakagawa, H. ....(A) 588
sustained protection against . . . , Lack of, in C3H mice vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with *Mycobacterium bovis* (BCG). TURCOTTE, R. and LEMIEUX, S. .....(O) 494

Muscle(s),
— reinnervation, Acceleration by isaxonine of; electrophysiological demonstration in leprotic neuropathy. Sebille, A., *et al.* .....(A) 565
posterior tibial, Transplantation of, for correcting leprous foot drop. .....(A) 134

Mycobacteria,
antigens of, groups of shared or species specific, preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to. Stanford, J. L., *et al.* .....(A) 253
atypical, drug sensitivity test strategy for. Hejny, J. .....(A) 407
certain soluble cytoplasmic . . . antigens, Double-blind trial on the effect of, on the late reactivity to lepromin. HADDAD, N., *et al.* .....(O) 325
combination of isoniazid, prothionamide and dapsone against *Mycobacterium leprae* and some other . . . , Activity of. Pattyn, S. R., *et al.* .....(A) 387
comparison of *M. leprae* whole organisms with other . . ., Leprosy ELISA antigen coating buffers and antigens. Naka, S. O. and Douglas, J. T. .....(A) 600
immunological studies with sulpholipids of. Khuller, G. K., *et al.* .....(A) 567
intra-cellular, in experimental mouse tuberculosis, electron microscopy study of. Kanai, K., *et al.* .....(A) 135
isolation of fastidiously growing . . . from armadillo livers infected with *Mycobacterium leprae*. PORTAELS, F. and PATTYN, S. R. .....(C) 370
mycobacterial antigens in leprosy tissues, Demonstration of. MSHANA, R. N., *et al.* ..(O) 1
mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy, Prostaglandin-dependent regulation of the *in vitro* proliferative response to. Bahr, G. M., *et al.* .....(A) 129
Nocardia-like . . . isolated from natural habitats in Zaire. Portaels, F., *et al.* .....(A) 408
non-mycobacterial stimulants, tuberculin purified protein derivative and; effect of dapsone treatment on the response to *Mycobacterium leprae* antigens. *In vitro*

lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* ....(O) 455
of *Mycobacterium scrofulaceum* type isolated from rat or mice lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. ....(A) 555
radiometric measurement of differential metabolism of fatty acid by. CAMARGO, E. E., *et al.* ....(O) 200
scotochromogenic, Studies on the lipids of *Mycobacterium gordonae* in comparison with those of *M. leprae* and of some other. Daffe, M., *et al.* ....(A) 400
Spontaneous release of mycophages from lysogenic bovine strains. Tageldin, M. H., *et al.* ....(A) 268
viability of . . . cells, fluorescent staining procedure for determining. KVACH, J. and VERAS, J. R. ....(O) 183

Mycobacterium avium,
susceptibility of, of various inbred strains of mice. I. On the cases with intraperitoneal infection. Tanemura, M. ....(A) 402
II. On the cases with subcutaneous infection. Tanemura, M. ....(A) 402
—, to, of C3H/H3 mice. Kawaguchi, Y. *et al.* ....(A) 558

Mycobacterium bovis,
antigenic diversity of *Mycobacterium tuberculosis* and . . . detected by means of monoclonal antibodies. Coates, A. R. M., *et al.* ....(A) 225
— (BCG), Lack of a sustained protection against murine leprosy in C3H mice vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with. TURCOTTE, R. and LEMIEUX, S. ....(O) 494
—, —, vaccination, Effect of, upon *Mycobacterium lepraemurium* infection. Lefford, M. J., *et al.* ....(A) 133
Ultrastructural characteristics of . . . BCG and *Mycobacterium leprae*. BINKHUYSEN, F. and DAS, P. K. ....(O) 76

Mycobacterium chelonei,
identification of, by thin-layer chromatographic analysis of whole-organism methanolysates. Goodfellow, M. and Minnikin, D. E. ....(A) 267
In vitro susceptibility of *Mycobacterium fortuitum* and . . . to cefoxitin. Casal, M. and Rodriguez, F. ....(A) 566
isoelectric focusing studies on. Sparks, J. and Ross, G. W. ....(A) 268

Mycobacterium fortuitum,
In vitro susceptibility of . . . and *Mycobacterium chelonei* to cefoxitin. Casal, M. and Rodriguez, F. ....(A) 566

Mycobacterium gordonae,
lipids of, in comparison with those of *M. leprae* and of some other scotochromogenic mycobacteria, Studies on. Daffe, M., *et al.* ....(A) 400

Mycobacterium intracellulare,
clofazimine against, Dynamic aspects of the activity of. Gangadharam, P. R., *et al.* ...(A) 126

Mycobacterium leprae,
adenosine triphosphate content of, effect of purification procedures. DHOPLE, A. M. and STORRS, E. E. ....(O) 83
and the host response. Harboe, M. ....(A) 261
antigenic analysis of, in lepromins with reference to the delayed type of hypersensitivity. Sengupta, U., *et al.* ....(A) 594
antileprosy drugs on glycolytic processes in rats infected with . . ., influence of. Rezaev, A. A. ....(A) 245
armadillo-derived, epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from. Part 1. Leprosy patients. SHIELD, M. J., *et al.* ....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. ....(O) 446
Biochemical correlation of *M. vaccae* with. Dutta, A. K., *et al.* ....(A) 554
Class specific anti-. . . antibody assay in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* ....(O) 271

combined chemotherapy against, model for the development of. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. SEYDEL, J. K. and WEMPE, E. G. ....(O) 20
cultivation of, in cell culture under regulation of redox potential at environment, Attempts at. Matsuo, Y. and Tatsukawa, H. ....(A) 556
—, the neglected priority. KATO, L. ....(C) 368
cycloheximide for cultivating . . . and *Mycobacterium lepraemurium* in cell culture, Use of. Matsuo, Y. ....(A) 578
dapsone (DDS), Effect of, on nude mice experimentally infected with. The study of leprosy chemotherapy in nude mice. Yoneda, K., *et al.* ....(A) 582
—, -resistant, Increase in prevalance of leprosy caused by. ....(N) 234
—, -resistant, Rapid macrophage culture method for detection of. Nath, I., *et al.* ....(A) 244
—, treatment, effect of, on the response to . . . antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* ..(O) 455
deoxy fructo serotonin (DFS), Effect of, on the multiplication of . . . in mouse foot pad. Balakrishnan, S., *et al.* ....(A) 535
diacyl phthioceral in secretions from, Structure and antigenicity of the specific phenolic glycolipid antigens and a related. Hunter, S. W. *et al.* ....(A) 591
DNA isolated from: genome size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation. Imaeda, T., *et al.* ....(A) 400
effect of, on phagosome-lysosome fusion in human macrophages. Scollard, D. M. and Gardner, I. D. ....(A) 596
fastidiously growing mycobacteria from armadillo livers infected with . . ., Isolation of. PORTAELS, F. and PATTYN, S. R. ....(C) 370
growth and death of . . . *in vivo,* Observations, calculations, and speculations on. Hastings, R. C. and Morales, M. J. ....(A) 579
—, of, in experimental animals and on artificial media. Pattyn, S. R. and Portaels, F. ..(A) 256
—, of, on M-Y 14b agar medium, Failure to validate. NAKAMURA, M., *et al.* ....(O) 480
—, of *Mycobacterium marinum* and . . . in mice, effect of body temperature and cell-mediated immunity on. Lancaster, R. D., *et al.* ....(A) 556
hapten modified, Improved leucocyte migration inhibition response of leucocytes from lepromatous leprosy patients with. Fotedar, A., *et al.* ....(A) 547
HLA-linked control of the course of . . . infections. de Vries, R. R. P. *et al.* ....(A) 260
IgA and IgM antibodies against . . . in cord sera and in patients with leprosy: An indicator of intrauterine infection in leprosy. Melsom, R., *et al.* ....(A) 397
immunoepidemiological studies on subclinical infection with. III. Geographic distribution of FLA-ABS test positive responders with special reference to their possible source of infection. Abe, M., *et al.* ....(A) 600
Immunoglobulin class specific antibodies in . . . in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Melsom, R., *et al.* ....(A) 397
—, G and M antibody responses to, in relation to various disease patterns; Humoral immunity in leprosy. Touw, J., *et al.* ....(A) 553
Immunotherapy with a mixture of . . . and BCG in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., *et al.* ....(O) 415
in vitro effects of a suspension of . . . on the phagocytosis and lysis of candida by neutrophils (preliminary communication). Fliess, E. L., *et al.* ....(A) 394
—, enhancement of lymphoproliferative response to, by the inhibition of biosynthesis of prostaglandins. Izumi, S., *et al.* ....(A) 595
inoculation of, into the 'rhino mouse'. Kohsaka, K., *et al.* ....(A) 583
isoniazid, prothionamide and dapsone against . . . and some other mycobacteria, Activity of the combination of. Pattyn, S. R., *et al.* ....(A) 387
lipidic constituents of, isolated from experimentally infected armadillo. Asselineau, C., *et al.* ....(A) 131
lipids of *Mycobacterium gordonae* in comparison with those of . . . and of some other scotochromogenic mycobacteria, Studies on. Daffe, M., *et al.* ....(A) 400
lymphocyte transformation test (LTT) by phytohemagglutinin, lepromin and . . . in

lepromatous leprosy patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* .....(A) 548
monoclonal antibodies to . . ., production and initial characterization of; Immunochemical characterization of antigens of the leprosy bacillus. Miller, R. A., *et al.* ..(A) 593
—, —, —, —, Production and partial characterization of. Gillis, R. P. and Buchanan, T. M. .....(A) 547
— glycolipid-1 antigen, Antibody responses of leprosy patients to. Umland, E. T., *et al.* .....(A) 592
— isolated from the lymph of a lepromatous leprosy patient by means of the freeze-fracture technique, Studies on. Sanabria Negrin, J. G., *et al.* .....(A) 556
— precursor coccoid organism, Inhibition of foot pad multiplication of, and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* .....(A) 400
—, —, —, —, Skin test response to, in a high leprosy endemic area as compared to lepromin. Chatterjee, B. R. .....(A) 400
— whole organisms, comparison of, with other mycobacteria; Leprosy ELISA antigen coating buffers and antigens. Naka, S. O. and Douglas, J. T. .....(A) 600
Mycobacterium smegmatis peroxidase; cross-reacting antigen with. Stavri, D., *et al.* ..(A) 399
Mycobacterial strains adapted to cultures separated from human lepromas. Identifying characteristics vis-a-vis . . . . Coudert, J., *et al.* .....(A) 554
nerve lesions of experimental animals inoculated with . . ., Comparative study of. Nishiura, M. and Fukunishi, Y. .....(A) 589
non-cultivable acid-fast bacilli in the environment and their relationship to, Occurrence of. Kaxda, J. .....(A) 262
novel phenolic glycolipid from . . . possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. .....(A) 132
pathomorphological changes in the internal organs of intact and . . . infected nine-banded armadillos. Vishnevetsky, F. E. and Juscenko, A. A. .....(A) 257
peribacillary substance of, Biochemical study of. Fukunishi, Y., *et al.* .....(A) 589
Propionibacterium acnes treatment, Effects of, on the course of . . . infection in mice. Krahenbuhl, J. L., *et al.* .....(A) 558
purified antigen of, and tuberculin PPD, *In vitro* lymphocyte stimulation using. Closs, O. and Reitan, L. J. .....(A) 259
—, armadillo-derived, in man, Testing of. (IMMLEP). .....(N) 378
—, glycolipid from, Serological activity of. PAYNE, S. N., *et al.* .....(C) 220
—, suspensions of, Preliminary studies of the metabolic activity of. Khanolkar, S. R. .....(A) 401
rifampicins against, comparison of the bactericidal activity of a series of. Pattyn, S. R. .....(A) 538
sciatic nerve compound action potential *in vitro* in normal and . . . infected mice, study of. Vidyasagar, P. B., *et al.* .....(A) 401
skin scrape and skin biopsy methods in mouse foot pad experiments with, comparison of. Venkataramanaiah, H. N., *et al.* .....(A) 560
specific antibodies to . . . by counter current electrophoresis, Demonstration of. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. .....(A) 396
superoxide dismutase, peroxidatic activity and catalase in . . . purified with armadillo liver. Wheeler, P. R. and Gregory, D. .....(A) 557
susceptibility of the armadillo to . . . infection, an index of; a preliminary report. Tissue response to lepromin. JOB, C. K., *et al.* .....(O) 177
testing drug activity against, Statistical analysis of results obtained by two methods for. SHEPARD, C. C. .....(O) 96
^{3}H-thymidine in, Incorporation of, within differentiated human macrophages. Prasad, H. K. and Nath, I. .....(A) 132
ultrastructural characteristics of *Mycobacterium bovis* BCG and . . . BINKHUYSEN, F. and DAS, P. K. .....(O) 76
uptake of 3,4-dihydroxy[^{3}H]phenylalamine by . . . isolated from frozen (−80°C) armadillo tissue. Khanolkar, S. R., *et al.* .....(A) 555
viability of, under normal and adverse atmospheric conditions. Kaur, S., *et al.* .....(A) 555

Mycobacterium lepraemurium,
antibacterial resistance in mice infected with. Patel, P. J. .....(A) 133
antigen-specific reactions and resistance to . . . infection in mice, lack of correlation between. Curtis, J., *et al.* .....(A) 256
cycloheximide for cultivating *Mycobacterium leprae* and . . . in cell culture, Use of. Matsuo, Y. .....(A) 578
experimental infection with, in the CBA/J mice. Effects of preimmunization on the evolution of the disease. Corona, C. J. J., *et al.* .....(A) 402
—, leprosy with, in hairless mice (*Mus musculus*). Packchanian, E., *et al.* .....(A) 560
growth of, in cell-free liquid medium, Effect of pantoyl lactone on. Nakamura, M. .....(A) 556
—, —, stimulation of, in cell-free liquid medium by aspartic acid, sucrose, liposome, thymidine, and deoxyuridine (NDLASU medium). Nakamura, M. .....(A) 578
—, —, —, —, —, —, —, —, by DL aspartic acid. NAKAMURA, M. .....(O) 193
—, —, —, —, —, —, —, —, by vitamin K3 and B12. Nakamura, M. .....(A) 401
in vitro cultivation of, and its identification by animal inoculation. Ishaque, M. .....(A) 132
—, —, growth of, transition from *in vivo* grown to *in vitro* adaptation. Dhople, A. M. and Hanks, J. H. .....(A) 255
—, —, —, —, under the influence of macrophage cultures. Matsuo, Y. and Tatsukawa, H. .....(A) 401
macrophages and protective immunity in . . . infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. .....(A) 560
mice infected with, strain difference of immune responses in. Hirooka, Y., *et al.* .....(A) 558
murine leprosy in C3H mice vaccinated with extracts of . . . in admixture with *Mycobacterium bovis* (BCG), Lack of a sustained protection against. TURCOTTE, R. and LEMIEUX, S. .....(O) 494
Mycobacterium bovis BCG vaccination, Effect of, upon . . . infection. Lefford, M. J., *et al.* .....(A) 133
— antigens at the infection site, Repeated delayed-type hypersensitivity reaction against, do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. ..(A) 397
— grown in the Ogawa yolk medium, Study of growth factor for. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M. .....(A) 559
oxydative phosphorylation in. Ishaque, M., *et al.* .....(A) 400
pathogenicity in mice and the ability of . . . to grow in tissue culture cells, relationship between. Nomaguchi, H., *et al.* .....(A) 578
Phagocytosis in leprosy. 5. Effect of the infection with . . . on the level of diverse hydrolic lysosomal enzymes of murine peritoneal macrophages. ROJAS-ESPINOSA, O., *et al.* .....(O) 306

Mycobacterium marinum,
body temperature and cell-mediated immunity, effect of, on the growth of . . . and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* .....(A) 556
infection in the hind foot pad with, Response in distant lymph nodes of mice to. Mor, N., *et al.* .....(A) 559
—, with, Response in the hind foot pad and popliteal lymph node of C56Bl mice to. Mor, N., *et al.* .....(A) 559
intraperitoneal vaccination against challenge in the foot pad with, Protection of mice by. Ng, H., *et al.* .....(A) 560
intravenous infection with, Survival of BALB/c mice after. Ng, H., *et al.* .....(A) 560

Mycobacterium phlei,
lipid composition of, Effect of growth temperature and exogenous fatty acids on. Taneja, R., *et al.* .....(A) 567

Mycobacterium scrofulaceum,
mycobacteria of . . . type isolated from rat or mice lepromata are not aetiologic agents of murine leprosy. Ishaque, M. .....(A) 555

Mycobacterium smegmatis,
— peroxidase, cross-reacting antigen with *Mycobacterium leprae*. Stavri, D., *et al.* ...(A) 399

Mycobacterium tuberculosis,
antigenic diversity of . . . and *Mycobacterium bovis* detected by means of monoclonal antibodies. Coates, A. R. M., *et al.* .....(A) 255

— H37Ra culture filtrate, Isolation and partial characterization of the most immunologically reactive antigen from. Reich, M., *et al.* ....(A) 567
rifampicin and isoniazid in strains of, Resistance to. Siddiqi, S. H., *et al.* ....(A) 409

Mycobacterium vaccae,
biochemical correlation of . . . with *M. leprae*. Dutta, A. K., *et al.* ....(A) 554

National Hansen's Disease Center,
Audio-visual loan program at. ....(N) 516
International seminars on leprosy sponsored by American Leprosy Missions and. . . .(N) 381

Nepal,
Green Pastures Leprosy Hospital, Ocular findings in leprosy: results of a survey in. Brandt, F., *et al.* ....(A) 128
Malunga, Ocular findings in leprous patients. A report of a survey in. Brandt, F. and Malla, O. K. ....(A) 128
Nepal Leprosy Relief Association. Shrestha, K. B. ....(N) 123

Nerve(s),
— abscess in lepromatous leprosy. Malaviya, G. N., *et al.* ....(A) 543
— damage in leprosy; a teased fibre study of sciatic . . . in experimental mice. Bhat, R. and Vaidya, M. C. ....(A) 557
—, —, —, —, Immunopathology of. MSHANA, R. N., *et al.* ....(C) 367
—, —, in tuberculoid leprosy. Reddy, P. K. and Prabhudass, N. ....(A) 545
— lesions of experimental animals inoculated with *M. leprae*. Comparative study of. Nishiura, M. and Fukunishi, Y. ....(A) 589
sciatic . . . compound action potential *in vitro* in normal and *M. leprae* infected mice, study of. Vidyasagar, P. B., *et al.* ....(A) 401
skin and peripheral, Discrepancy in the histopathological features of leprosy lesions in. Report of a preliminary study. Srinivasan, J., *et al.* ....(A) 553
supraorbital, in leprosy, Compression neuritis of. Vaquero, N. L. and Soto, I. ....(A) 393

Neuritis,
compression . . . of the supraorbital nerve in leprosy. Vaquero, N. L. and Soto, I. . . .(A) 393
in pregnancy and lactation. DUNCAN, M. E. and PEARSON, J. M. H. ....(O) 31
leprous, Immunological implications of necrotic, cellular and vascular changes in: light and electron microscopy. Dastur, D. K., *et al.* ....(A) 249
—, perineurotropic derivatives of acidic anti-inflammatory drugs for treatment of, Fundamental studies on the possibility of. Tsutsumi, S. and Gidoh, M. ....(A) 590
—, Rehabilitation in leprosy. Abraham, J. C. ....(A) 266
—, ulnar . . ., Surgical management of. Kumar, K. ....(A) 406
ulnar . . . of leprosy, Role of surgical decompression in. Malaviya, G. N. and Ramu, G. . .(A) 565

Neuropathy,
autonomic functions in leprosy, study of. Dabholkar, V. R., *et al.* ....(A) 541
cardiovascular autonomic functions in leprosy. Sahasranam, K. V., *et al.* ....(A) 546
classification and treatment of, in Hansen's disease. Charosky, C. B. ....(A) 267
leprotic, Acceleration by isaxonine of muscle reinnervation; electrophysical demonstration in. Sebille, A., *et al.* ....(A) 565
neuropathic reactions in leprosy. Espana, A. ....(A) 389
Peripheral Neuropathies; Report of a WHO Study Group. ....(B) 239

Neutrophils,
in vitro effects of a suspension of *Mycobacterium leprae* on the phagocytosis and lysis of candida by . . . (preliminary communication). Fliess, E. L., *et al.* ....(A) 394
motility of . . . and transformation of lymphocytes from normal individuals, *in vitro* and *in vivo* effects of clofazimine on. Gatner, E. M. S., *et al.* ....(A) 386
— and lymphocyte functions in normal individuals and patients with lepromatous leprosy, Effects of clofazimine alone or combined with dapsone on. Van Rensburg, C. E., *et al.* ....(A) 539

New Zealand,
Pan Pacific Leprosy Symposium. Hargrave, J. C. ....(N) 232
The Leprosy Trust Board. ....(N) 237

Nigeria,
Hepatitis-B virus infection in patients with leprosy: A serological study in a leprosarium in northern . . . . Fankule, Y. M. and Whittle, H. C. .....(A) 390

Norway,
disappearance of leprosy from, Epidemiological aspects and implications of; some factors contributing to the decline. Irgens, L. M. .....(A) 261

Nose,
in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., *et al.* ..(O) 58
leprosy of. Rossi Vargas, J. .....(A) 392

Nucleic acids,
fractionated, Skin tests with. Assessment of Dharmendra antigen. VI. Sinha, S., *et al.* ..(A) 553

Nutrition,
delayed hypersensitivity after BCG in preschool children in relation to their nutritional status. Seth, V., *et al.* .....(A) 268
influence of, on postvaccinal tuberculin sensitivity. Satyanarayana, K., *et al.* .....(A) 135

Obituaries (*see also* under surname),
Karat, Aaron Benedict Abiel. Brand, P. W. .....(Ob) 359
Lara, Casimiro B. Jose, F. A., Jr. .....(Ob) 213
Sagher, Felix. Sheskin, J. and Levy, L. .....(Ob) 508

Ocular (*see also* Eye),
— disease in leprosy in Madagascar, Contribution to the study of. Andriantsoa-Rasoavelonoro, V., *et al.* .....(A) 127
— findings in leprosy: results of a survey in the Green Pastures Leprosy Hospital, Nepal. Brandt, F., *et al.* .....(A) 128
—, —, in leprous patients. Report of a survey in Malunga (Nepal). Brandt, F. and Malla, O. K. .....(A) 128
— lesions in lepromatous leprosy. Chovet, M., *et al.* .....(A) 128
—, —, in leprosy. Reddy, S. C., *et al.* .....(A) 247

OMSLEP,
OMSLEP. Recording and Reporting System for Leprosy Patients. Lechat, M. F., *et al.* .....(B) 524

Onchocerciasis,
detection of circulating antigens in. Ouaissi, A., *et al.* .....(A) 267
paraclinical study of, in a leprous and nonleprous population (Mali). Penchenier, L., *et al.* .....(A) 392

Papua New Guinea,
Xylose absorption in Papua New Guineans with leprosy. Cook, G. C. .....(A) 541

Paramedics,
employment sought for African paramedicals. .....(N) 119
Teaching Guide for Paramedical Workers in Leprosy. Vol. 1. Chaudhary, D. S. .....(B) 383

Pathogenesis,
novel phenolic glycolipid from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. .....(A) 132
of disease, role of regional body temperature in. Robard, D. .....(A) 131
— and classification of polar tuberculoid leprosy. Ridley, D. S. .....(A) 252
pathogenicity in mice and the ability of *M. lepraemurium* to grow in tissue culture cells, relationship between. Nomaguchi, H., *et al.* .....(A) 578

Pathology,
clinico-pathological study of so-called immune zones in leprosy. Sahni, U., *et al.* .....(A) 546
—, —, of testicular involvement in leprosy. Kumar, B., *et al.* .....(A) 543
pathomorphology of leprosy, modern views of. Vishnevetsky, F. E. and Juscenko, A. A. .....(A) 254

serum lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* .....(A) 246

Peroxidase,
Mycobacterium smegmatis . . ., cross-reacting antigen with *Mycobacterium leprae*. Stavri, D., *et al.* .....(A) 399
superoxide dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with armadillo liver. Wheeler, P. F. and Gregory, D. .....(A) 557

Phagocytosis,
in leprosy. 5. Effect of the infection with *Mycobacterium lepraemurium* on the level of diverse hydrolic lysosomal enzymes of murine peritoneal macrophages. ROJAS-ESPINOSA, O., *et al.* .....(O) 306
— and lysis of candida by neutrophils, *in vitro* effects of a suspension of *Mycobacterium leprae* on, (preliminary communication). Fliess, E. L., *et al.* .....(A) 394

Phenolic glycolipid(s),
novel . . . from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. .....(A) 132
structure and antigenicity of the specific . . . antigens and a related diacyl phthioceral in secretions from *Mycobacterium leprae*. Hunter, S. W., *et al.* .....(A) 591

Philippines, The,
Philippine Journal of Dermatology and Leprosy. Reyes-Javier, P. D. .....(N) 233
Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. .....(N) 124

Phospholipid(s),
— deacylating activities in murine leprosy bacilli. Kashiwabara, Y. and Nakagawa, H. ..(A) 588

Phytohemagglutinin,
lymphocyte transformation test (LTT) by . . . , lepromin and *M. leprae* in lepromatous leprosy patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* .....(A) 548
— (PHA)-induced lymphocyte transformation, *In vitro* effect of DDS on. Ghei, S. K., *et al.* .....(A) 395

Pregnancy,
and leprosy: the consequence of alterations of cell-mediated and humoral immunity during . . . and lactation. DUNCAN, M. E., *et al.* .....(O) 425
Clofazimine in . . . complicated by leprosy. Farb, H., *et al.* .....(A) 243
neuritis in . . . and lactation. DUNCAN, M. E. and PEARSON, J. M. H. .....(O) 31

Properdin,
genetic polymorphisms of . . . factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and health controls from Thailand. Greiner, J., *et al.* .....(A) 130

Prostaglandin(s),
inhibition of biosynthesis of, *In vitro* enhancement of lymphoproliferative response to *M. leprae* by. Izumi, S., *et al.* .....(A) 595
— dependent regulation of the *in vitro* proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* .....(A) 129

Prosthetics,
peg prosthesis in leprosy, Observations on. Kulkarni, V. N. and Mehta, J. M. .....(A) 564

Protein(s),
egg yolk . . . fraction and effect of reducing reagents. Study of growth factor for *Mycobacterium lepraemurium* grown in the Ogawa yolk medium. II. Mori, T. and Nyein, M. .....(A) 559
electrophoretic pattern of, in lepromatous leprosy. Baji, P. S., *et al.* .....(A) 540
— deficiency, Disposition of dapsone in; an experimental study in mice. Venkatesan, K., *et al.* .....(A) 540

serum . . . bound fucose (PBF) in untreated leprosy patients. Venkatesan, K., *et al.* ..(A) 393
total and differential serum . . . and globulins in leprosy. Kumar, B., *et al.* .....(A) 543
tuberculin purified . . . derivative and non-mycobacterial stimulants, effect of dapsone treatment on the response to *Mycobacterium leprae* antigens. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* .....(O) 455

Prothionamide,
isoniazid, . . . and dapsone against *Mycobacterium leprae* and some other mycobacteria, Activity of. Pattyn, S. R., *et al.* .....(A) 387
low dosage, role of, with and without 4,4′-diaminodiphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis. Grosset, J., *et al.* ..(A) 407

Purified protein derivative (PPD),
in vitro lymphocyte stimulation using a purified antigen of *M. leprae* and tuberculin . . . . Closs, O. and Reitan, L. J. .....(A) 259
tuberculin . . . and non-mycobacterial stimulants; effect of dapsone treatment on the response to *Mycobacterium leprae* antigens. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* ..(O) 455

Radioimmunoassay,
and other serological tests and their application in epidemiological work. Harboe, M. .....(A) 261
of tuberculous antigen. Kadival, G. V., *et al.* .....(A) 567

Rat(s),
glycolytic processes in . . . infected with *M. leprae,* influence of antileprosy drugs on. Rezaev, A. A. .....(A) 245
mycobacteria of *Mycobacterium scrofulaceum* type isolated from . . . or mice lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. .....(A) 555
nude . . . as an experimental lepromatous leprosy model (continued): effects of carrageenans, splenectomy, and treatment with thymus cells. Nakamura, K. and Yogi, Y. .....(A) 587

Reaction(s),
antigen-specific, lack of correlation between . . . and resistance to *Mycobacterium lepraemurium* infection in mice. Curtis, J., *et al.* .....(A) 256
borderline-tuberculoid leprosy in . . . presenting as photodermatitis; a case report. Fekete, E., *et al.* .....(A) 390
early (Fernandez) and late (Mitsuda) . . ., Correlation between, in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials. Bechelli, L. M., *et al.* .....(A) 547
egg-yolk, produced by human and murine leprosy lesions and its cultural significance on primary isolation. Koseki, Y., *et al.* .....(A) 577
etiopathogenesis of reactional episodes. Pacin, A. and Fliess, E. L. .....(A) 398
hansenic, Dimorphous hanseniasis with outbreaks of, and visceral lesions. .....(A) 246
hypersensitivity, Pharmacologically active mediators of, in the blood of lepromatous patients with erythema nodosum leprosum. Saha, K. and Lahiri, S. C. .....(A) 252
interdermal . . . following integral lepromin and lepromin treated with ultrasound in normal individuals, study comparing. Karazawa, E. H., *et al.* .....(A) 550
lepra, Osteo-articular changes in. Charosky, C. B. .....(A) 388
—, progressive. Guha, P. K. and Ghosh, M. .....(A) 542
—, thalidomide treatment of, Iron content of skin before and after. Sheskin, J., *et al.* .....(A) 247
—, visceral manifestations of. Ortiz, M. C. .....(A) 391
Mitsuda, comparative study with whole human and armadillo lepromin in 50 leprosy patients. Zambrano, M. T., *et al.* .....(A) 129
necrotizing lepra, spectrum of. (Allergic cutaneous vasculitis; Lucio phenomenon.) A proposed intermediate lepra reaction. Peyri, L., *et al.* .....(A) 545
neuropathic, in leprosy. Espana, A. .....(A) 389
repeated delayed-type hypersensitivity, against *Mycobacterium lepraemurium* anti-

gens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. ....(A) 397
Type 1 lepra, induced by lepromin test; a case report. Dong Li-Wen, *et al.* ....(A) 541
type 1 . . . , short-term, multi-drug chemotherapy of leprosy and. PFALTZGRAFF, R. E. ..(C) 365

Rees, Dr. R. J. W.,
to retire from National Institute for Medical Research. ....(N) 381

Rehabilitation,
All Africa Leprosy and Rehabilitation Training Centre (ALERT) international courses program; 1982 (Ethiopia) ....(N) 226
ILO/DANIDA Asian regional seminar on vocational rehabilitation; Bombay (India). ..(N) 227
in leprosy; leprous neuritis. Abraham, J. C. ....(A) 266
—, —, socio-anthropological aspects. Pina, N. C. and Manzi, R. O. ....(A) 564
metatarsal head pressure (MHP) sores in leprosy patients. Pati, L. and Behera, F. ....(A) 406

Renal (*see also* Kidney(s)),
— amyloidosis complication of tuberculoid leprosy and plasma cell dyscrasia; case reports of three patients. Seggie, J. and Gelfand, M. ....(A) 546
— changes in leprosy, Study of. PHADNIS, M. C., *et al.* ....(O) 143
— transplantation in leprosy. DATE, A., *et al.* ....(O) 56

Respiratory tract,
Leprosy of the Upper Respiratory Tract. Atlas of Clinical Picture and Notes on the Research (1938–1943). Yoshie, Y. ....(B) 384

Rheumatoid arthritis,
detection of anti-collagen type I and II antibodies by an immunoenzymatic technique (ELISA): results in . . . , systemic lupus erythematosus and leprosy. Meghlaoui, A. ..(A) 250
does . . . have a clinicopathological spectrum similar to that of leprosy. Panayi, G. S. ....(A) 392

Ridley-Jopling scale,
in clinical practice, Applicability of . . . Verma, K. C., *et al.* ....(A) 393

Rifampin,
bactericidal activity of a series of . . . against *Mycobacterium leprae*, comparison of. Pattyn, S. R. ....(A) 538
immunodepressive effect of . . . (RFP) on cell-mediated immunity of guinea pigs examined by rabbit red blood cell rosette formation method. Gidoh, M. and Tsutsumi, S. ....(A) 386
resistance to . . . and isoniazid in strains of *Mycobacterium tuberculosis*. Siddiqi, S. H., *et al.* ....(A) 409
—, once-monthly, plus daily dapsone in initial treatment of lepromatous leprosy. Yawalkar, S. J., *et al.* ....(A) 540
— treatment of paucibacillary leprosy, Follow-up on short-course two months'. Warndorff, J., *et al.* ....(A) 245
therapeutic effect of oximes of 3-formylrifamycin SV in the treatment of leprosy. Ji Baohung, *et al.* ....(A) 537
three drugs used most frequently for leprosy are dapsone, . . . and clofazimine. ....(N) 235

Sarcoidosis,
tuberculoid leprosy or . . . ; a diagnostic dilemma. Ramanujam, K. ....(A) 545

Sagher, Felix,
obituary, Sheskin, J. and Levy, L. ....(Ob) 508

Sera, of leprosy patients,
adenosine deaminase activity in, study of. Chon, J. Y., *et al.* ....(A) 394
anomalous isoenzymes of lactate dehydrogenase in. Saoji, A. M. and Kelkar, S. S. ..(A) 557
antibodies to sulfolipids in. KHULLER, G. K., *et al.* ....(O) 319
beta hydroxy beta methyl glutaryl CoA reductase in . . . , Indirect assay of; a further probe into cholesterol metabolism. Kannan, K. B., *et al.* ....(A) 542
cord sera, IgA and IgM antibodies against *Mycobacterium leprae* in . . . and in patients with leprosy: indicator of intrauterine infection in leprosy. Melsom, R., *et al.* ..(A) 397

determination of three main antileprosy drugs and their main metabolites in serum by high performance liquid chromatography. Gidoh, M., *et al.* .....(A) 244
lactic dehydrogenase isoenzymes in. Garcia, R., *et al.* .....(A) 542
normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy, Cutaneous response to. Corona, C. J., *et al.* .....(A) 249
—, enzyme profile in tuberculoid leprosy. Bulakh, P. M., *et al.* .....(A) 541
—, lactate dehydrogenase isoenzyme patterns in leprosy, Qualitative studies of. Saoji, A. M. and Kelkar, S. S. .....(A) 247
—, lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* .....(A) 246
—, immunoglobulins and autoantibodies during and after erythema nodosum leprosum (ENL). SHARMA, V. K., *et al.* .....(O) 159
—, inhibitory factor in lepromatous leprosy; its effect on the pre-S-phase cell cycle kinetics of mitogen-stimulated normal human lymphocytes. Potts, R. C., *et al.* ....(A) 251
—, protein bound fucose (PBF) in untreated leprosy patients. Venkatesan, K., *et al.* .....(A) 393
—, proteins and globulins in leprosy, Total and differential. Kumar, B., *et al.* .....(A) 543
—, trace elements and vitamin A in leprosy subtypes. Sher, R., *et al.* .....(A) 128

Skin,
free . . . flap, Surgical treatment of plantar ulcer with, in leprosy patients: a case report. Dong Li-Wen, *et al.* .....(A) 267
histopathological features of leprosy lesions in the . . . and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., *et al.* .....(A) 553
human leprosy . . . lesions, Imunohistopathologic study of β-glucuronidase and lysozyme in. Matsuo, E., *et al.* .....(A) 599
ichthyotic and nonichthyotic . . . and plasma of leprosy patients with and without clofazimine therapy, Vitamin A levels of. Bharadwaj, V. P., *et al.* .....(A) 535
Iron content of . . . before and after thalidomide treatment of lepra reaction. Sheskin, J., *et al.* .....(A) 247
malignant . . . tumors, Leprosy and. Cardama, J. E., *et al.* .....(A) 388
— lesions across the spectrum of leprosy, immunoperoxidase study of immunological factors in. RIDLEY, M. J., *et al.* .....(O) 11
— of leprosy patients, apparently normal, Histologic profile in. Sakuntala, R., *et al.* ..(A) 552
— scrape and . . . biopsy methods, comparison of, in mouse foot pad experiments with *M. leprae*. Venkataramanaiah, H. N., *et al.* .....(A) 560
— smears of leprosy patients, study on selection of sites for acid-fast bacilli in. Kim, Y. .....(A) 391
specific . . . delayed hypersensitivity (DH) inducing antigens from lepromin, Attempts for purification of. Assessment of Dharmendra antigen. V. Sengupta, U., *et al.* .....(A) 552

Skin test(s),
— reagent LRA6, a cell-free extract from armadillo-derived *Mycobacterium leprae*, epidemiological evaluation, in Burma, of. Part 1. Leprosy patients. SHIELD, M. J., *et al.* .....(O) 436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. .....(O) 446
— reagents, control of specificity of. Magnusson, M. .....(A) 263
— response, Specific, in children of patients with indeterminate leprosy, tuberculoid leprosy, and lepromatous leprosy. Gimenez, M. and Morini, J. C. .....(A) 395
—, —, to *M. leprae* precursor coccoid organisms in a high leprosy endemic area as compared to lepromin. Chatterjee, B. R. .....(A) 400
with fractionated nucleic acids. Assessment of Dharmendra antigen. VI. Sinha, S., *et al.* .....(A) 553

South Africa,
pattern of age-specific tuberculin hypersensitivity in two groups of South African schoolchildren. Gatner, E. M. S. and Rubinstein, E. .....(A) 134

Spain,
International courses on leprosy at Fontilles. .....(N) 378

Spleen,
effects of carrageenans, splenectomy, and treatment with thymus cells; the nude rat as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. ....(A) 587
inhibition of foot pad multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* ....(A) 400
role of the . . . in the formation of the lepromatoid lesions; the hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. ....(A) 586

Stain(s),
blood staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., *et al.* ....(A) 248
fluorescent staining procedure for determining the viability of mycobacterial cells. KVACH, J. and VERAS, J. R. ....(O) 183
oxidative acid-fast staining for non-deparaffinized sections of leprosy tissue, modified procedure of. Yong, Z. *et al.* ....(A) 131

Sulfone(s),
current status of. Consigli, C. A. ....(A) 385
Plasma-mediated sulfonamide resistance in *Haemophilus ducreyi*. Albritton, W. L., *et al.* ....(A) 406
— resistant leprosy, clinical and experimental studies on. Li Wenzhong, *et al.* ....(A) 126

Superoxide,
— dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with armadillo liver. Wheeler, P. F. and Gregory, D. ....(A) 557

Surgery,
acute onset in leprosy patients, Surgical problems of, and their management in leprosy control programmes. Prasad, S. B. ....(A) 565
Leprosy (transactions of the Seventh International Congress of Plastic and Reconstructive Surgery). Duerksen, F. ....(A) 405
leprous ulnar neuritis, Surgical management of. Kumar, K. ....(A) 406
plantar ulcer, surgical treatment of, with free skin flap in leprosy patients: case report. Dong Li-Wen, *et al.* ....(A) 267
sublimus tendons, Effects on fingers of leprosy patients having surgical removal of. Reddy, N. R. and Kolumban, S. L. ....(A) 406
ulnar neuritis of leprosy, Role of surgical decompression in. Malaviya, G. N. and Ramu, G. ....(A) 565

Switzerland,
Emmaus, 25th anniversary of. ....(N) 236
IMMLEP Steering Committee meetings. ....(N) 516
testing of purified armadillo-derived *Mycobacterium leprae* in man; IMMLEP ....(N) 378
THELEP reviews progress of field trials. ....(N) 379
THELEP seeks trial sites. ....(N) 379

Syphilis,
in Hansen's disease patients at Plaza Municipality (Cuba) during 1977, Serology to determine. Cardenas, Z. L., *et al.* ....(A) 541
in patients with Hansen's disease. MURRAY, K. A. ....(O) 152

Tanzania,
leprosy and the possible role of village 10-cell leaders in control in Muheza District, prevalence survey on. Van Praag, E. and Mwankemwa, S. A. ....(A) 266

Taste,
disturbance of, in leprosy. Soni, N. K. and Chatterji, P. ....(A) 248
loss of . . . and somatic sensations over the tongue in leprous facial palsy; a case report. Malaviya, G. N. and Ramu, G. ....(A) 391

Temperature,
body . . . and cell-mediated immunity, Effect of, on the growth of *Mycobacterium marinum* and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* ....(A) 556

—, —, regional, role of, in the pathogenesis of disease. Robard, D. .....(A) 131
growth . . . and exogenous fatty acids, Effect of, on the lipid composition of *Mycobacterium phlei*. Taneja, R., *et al.* .....(A) 567

Testes,
immunoreactivity *in vitro* to human . . . in patients with lepromatous leprosy. Wall, J. R. and Walters, B. A. J. .....(A) 255
testicular involvement in leprosy, Clinico-pathological study of. Kumar, B., *et al.* ....(A) 543

Tetanus,
natural resistance against, in patients with lepromatous leprosy. Saha, K., *et al.* .....(A) 392

Thailand,
clinical and epidemiological features of leprosy in two resettlement villages. Vithayasai, V., *et al.* .....(A) 601
genetic polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from . . . . Greiner, J., *et al.* .....(A) 130

Thalidomide,
does not affect polymorphonuclear leukocyte (PMN) chemotaxis. Miyachi, Y. and Ozaki, M. .....(A) 387
— treatment of lepra reaction, Iron content of skin before and after. Sheskin, J., *et al.* .....(A) 247

The Leprosy Mission (TLM),
Lady Richardson named chairman of. .....(N) 233
Miss Grace Bennett retires from, in Korea. .....(N) 376
— International teaching and learning in leprosy report for 1981. .....(N) 382

THELEP,
Annual report of IMMLEP and THELEP 1980–1981. .....(N) 233
reviews progress of field trials. .....(N) 379
seeks trial sites. .....(N) 379
Tenth meeting of THELEP Steering Committee held in Rangoon. .....(N) 225

Therapy,
clofazimine, Vitamin A levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without. Bharadwaj, V. P., *et al.* .....(A) 535
for leprosy, Intramuscular injection of dapsone in: a new approach. Modderman, E. S. M., *et al.* .....(A) 387
Therapeutic effect of oximes of 3-formylrifamycin SV in the treatment of leprosy. Ji Baohung, *et al.* .....(A) 537
tuberculosis, Immune responses and immunostimulation in. Gatner, E. M. S. and Anderson, R. .....(A) 566

Thiacetazone (TBI),
severe dermatitis induced by the use of, in the treatment of tuberculosis in the state of Rio Grande do Sul (Brazil). .....(A) 243

Thiazole(s),
thiocarbanilides derived from 2-(4′-aminophenyl) . . . and 4-(4′-aminophenyl) . . . for *in vitro* antituberculosis activity, Synthesis and study of. Nerurkar, C. B., *et al.* ..(A) 387
2-aryloxy thioisonicotinamides analogous to ethinonamide and . . . derived therefrom as antituberculosis agents, Synthesis and study of. Pendalwar, S. L., *et al.* .....(A) 387

Thymidine,
cell-free liquid medium by aspartic acid, sucrose, liposome, . . . , and deoxyuridine (NDLASU medium), Stimulation of growth of *Mycobacterium lepraemurium* in. Nakamura, M. .....(A) 578
^{3}H-thymidine in *Mycobacterium leprae* within differentiated human macrophages, Incorporation of. Prasad, H. K. and Nath, I. .....(A) 132

Thymosin,
pig's, combined with dapsone, Pilot-trial of treatment of leprosy by. .....(A) 551

Thymus,
— dependent lymphocytes in leprosy. I. T lymphocyte subpopulations defined by monoclonal antibodies. MSHANA, R. N., *et al.* .....(O) 291
treatment with . . . cells, nude rat as an experimental lepromatous leprosy model (continued): the effects of carrageenans, splenectomy, and. Nakamura, K. and Yogi, Y. .....(A) 587

Tissue(s),
frozen (−80°C) armadillo, Uptake of 3,4-dihydroxy[^{3}H]phenylalamine by *Mycobacterium leprae* isolated from. Khanolkar, S. R., *et al.* .....(A) 555
leprosy, Demonstration of mycobacterial antigens in. MSHANA, R. N., *et al.* .....(O) 1
non-deparaffinized sections of leprosy . . . , modified procedure of oxidative acid-fast staining for. Zhou Yong, *et al.* .....(A) 131
T cell subsets in the peripheral blood and . . . of patients with leprosy. Modlin, R. L., *et al.* .....(A) 596
— culture cells, relationship between pathogenicity in mice and the ability of *M. lepraemurium* to grow in. Nomaguchi, H., *et al.* .....(A) 578
— response to lepromin; an index of susceptibility of the armadillo to *M. leprae* infection; a preliminary report. JOB, C. K., *et al.* .....(O) 177

Tongue,
loss of taste and somatic sensations over the . . . in leprous facial palsy; a case report. Malaviya, G. N. and Ramu, G. .....(A) 391

Toxicity,
of clofazimine, Study of, with special reference to structural and functional status of small intestine. Kumar, B., *et al.* .....(A) 537

Transfusions,
of fresh blood, donated by healthy but lepromin positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated. Saha, K., *et al.* .....(A) 552

Trials,
double blind . . . on the effect of certain soluble cytoplasmic mycobacterial antigens on the late reactivity to lepromin. HADDAD, N., *et al.* .....(O) 325
pilot-. . . of treatment of leprosy by pig's thymosin combined with dapsone. .....(A) 551
short-term clinical . . . monitored by mouse foot pad inoculation, brief review of experiences with. Shepard, C. C. .....(A) 245
THELEP reviews progress of field . . . .(N) 379
THELEP seeks . . . sites. .....(N) 379
Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. .....(N) 124
three double-blind . . . , Correlation between early (Fernandez) and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy; tested with different concentrations of armadillo antigen in. Bechelli, L. M., *et al.* .....(A) 547

Tuberculin,
age-specific . . . hypersensitivity in two groups of South African schoolchildren, pattern of. Gatner, E. M. S. and Rubinstein, E. .....(A) 134
postvaccinal . . . sensitivity, Influence of nutrition on. Satyanarayana, K., *et al.* .....(A) 135
— PPD, *In vitro* lymphocyte stimulation using a purified antigen of *M. leprae* and. Closs, O. and Reitan, L. J. .....(A) 259
— purified protein derivative, effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, . . . and non-mycobacterial stimulants. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* .....(O) 455

Tuberculosis,
chemotherapy in pulmonary . . . , Shortest possible acceptable effective ambulatory. Mehrotra, M. L., *et al.* .....(A) 408
experimental mouse, electron microscopy study of intra-cellular mycobacteria in. Kanai, K., *et al.* .....(A) 135
—, —, role of low dosage prothionamide with and without 4,4′-diaminodiphenyl sulphone for use with isoniazid in the treatment of. Grosset, J., *et al.* .....(A) 407
immune complexes in the spectrum of. Brostoff, J., *et al.* .....(A) 134
—, responses and immunostimulation in . . . therapy. Gatner, E. M. S. and Anderson, R. .....(A) 566
patients with pulmonary . . . , Circulating immunoglobulin levels in, with special reference to IgE. Gatner, E. M. S., *et al.* .....(A) 566
—, with . . . or leprosy, Absence of antibodies to muramyl dipeptide in. Bahr, G. M., *et al.* .....(A) 394
—, —, —, —, —, Prostaglandin-dependent regulation of the *in vitro* proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from. Bahr, G. M., *et al.* .....(A) 129
pulmonary . . . patients, Immune status in. Mirza, A. .....(A) 567
thiacetazone in the treatment of, in the state of Rio Grande do Sul (Brazil), Severe dermatitis induced by the use of. .....(A) 243
— control: world review. .....(A) 568

Tumors,
malignant skin, Leprosy and. Cardama, J. E., *et al.* .....(A) 388

Ultrasound,
Hypodermitis sclerodermiformis; successful treatment with. Rowe, L. and Cantwell, A., Jr. .....(A) 408
interdermal reactions following integral lepromin and lepromin treated with . . . in normal individuals, study comparing the. Karazawa, E. H., *et al.* .....(A) 550

Ultrastructural characteristics,
features of the multiplication of human and murine leprosy bacilli in macrophages of nude mice. FUKUNISHI, Y., *et al.* .....(O) 68
of cells in lesions of lepromatous and tuberculoid leprosy. Liu Zijun, *et al.* .....(A) 551
of histoid leproma, Observations on. LIU JIHE, *et al.* .....(O) 471
of *Mycobacterium bovis* BCG and *Mycobacterium leprae*. BINKHUYSEN, F. and DAS, P. K. .....(O) 76
of the dermal microvasculature in leprosy. TURKEL, S. B., *et al.* .....(O) 164

United Kingdom,
International Seminar on the Prevention of Disablement. Browne, S. G. .....(N) 121
Lady Richardson named chairman of The Leprosy Mission. .....(N) 233
National Institute for Medical Research, Dr. R. J. W. Rees to retire from. .....(N) 381
The Leprosy Mission (TLM) International teaching and learning in leprosy report for 1981. .....(N) 382

U.S.A.,
American Association for the Advancement of Science, Prime Minister Gandhi (India) addresses the. .....(N) 522
Audio-visual loan program at National Hansen's Disease Center. .....(N) 516
closing of Public Health Service hospitals. .....(N) 234
Emmanuel Faria named to ALM Board. .....(N) 521
epidemiologic evaluation of leprosy in New York City. .....(A) 562
Heiser Program for Research in Leprosy; 1983 opportunities. .....(N) 380
—, —, the first five years. .....(N) 379
International seminars on leprosy sponsored by American Leprosy Missions and National Hansen's Disease Center. .....(N) 381
Leonard Wood Memorial Scientific Symposium, Bellagio, Italy, 2–4 June 1982. .....(N) 521

Leprosy Scientific Memoranda to resume in fall 1982 by Leonard Wood Memorial. . .(N) 522
1982 International Health Conference scheduled. .(N) 122
27th International Seminar on Leprosy, details announced. .(N) 234
233 new leprosy cases in. .(A) 258
unwanted import on the rise: leprosy. .(A) 563

U.S.–Japan Cooperative Medical Science Program,
Seventeenth Joint Leprosy Conference, Sendai, Japan, 25–27 July 1982. .(—) 569

Upper Volta,
four cases of dapsone resistant leprosy in. Pattyn, S. R., *et al.* .(A) 244

U.S.S.R.,
incidence of leprosy in family members of patients (according to the materials of the Astrakhan Zone). Kogan, V. R., *et al.* .(A) 262

Vaccination,
BCG . . . in leprosy. PRICE, J. E. .(E) 205
BCG . . . of children against leprosy in Uganda: final results. Stanley, S. J., *et al.* .(A) 265
intraperitoneal . . . against challenge in the foot pad with *Mycobacterium marinum*, Protection of. Ng, H., *et al.* .(A) 560
Mycobacterium bovis BCG . . . , Effect of, upon *Mycobacterium lepraemurium* infection. Lefford, M. J., *et al.* .(A) 133
with extracts of *Mycobacterium lepraemurium* in admixture with *Mycobacterium bovis* (BCG), Lack of a sustained protection against murine leprosy in C3H mice vaccinated. TURCOTTE, R. and LEMIEUX, S. .(O) 494

Vaccine,
BCG . . . induced lupus vulgaris. Izumi, A. K. and Matsunaga, J. .(A) 407
leprosy . . . (Letter to Editor). Brennan, P. J. .(A) 534
potential antileprosy . . . from killed ICRC bacilli; a clinicopathological study. Deo, M. G., *et al.* .(A) 130

Vasculitis,
allergic cutaneous . . .; (Lucio phenomenon). spectrum of the necrotizing lepra reactions. A proposed intermediate lepra reaction. Peyri, L., *et al.* .(A) 545
leukocytoclastic . . . . Mackel, S. E. and Jordan, R. E. .(A) 407

Visceral leprosy,
dimorphous hanseniasis with outbreaks of hansenic reaction and visceral lesions. .(A) 246
visceral manifestations of lepra reactions. Ortiz, M. C. .(A) 391

Vitamin A,
in leprosy subtypes, Serum trace elements and. Sher, R., *et al.* .(A) 128
— levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without clofazimine therapy. Bharadwaj, V. P., *et al.* .(A) 535

Vitamin B12,
growth stimulation of *Mycobacterium lepraemurium* in cell-free liquid medium by vitamin K3 and. Nakamura, M. .(A) 401

Vitamin K3,
growth stimulation of *Mycobacterium lepraemurium* in cell-free liquid medium by . . . and B12. Nakamura, M. .(A) 401

World Health Organization (WHO),
chemotherapy of leprosy for control programmes. .(A) 536
Kuala Lumpur meeting on social and economic aspects of leprosy (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases). .(N) 376
Report of a WHO study group. *Peripheral Neuropathies*. .(B) 239
testing of purified armadillo-derived *Mycobacterium leprae* in man; IMMLEP .(N) 378
THELEP reviews progress of field trials .(N) 379
THELEP seeks trial sites. .(N) 379

— and Council for International Organizations of Medical Sciences. *Proposed International Guidelines for Biomedical Research Involving Human Subjects.* .....(B) 383
— workshop, Bombay. *Urban Leprosy Control.* .....(B) 383

Xylose,
— absorption in Papua New Guineans with leprosy. Cook, G. C. .....(A) 541

Zaire,
Nocardia-like mycobacteria isolated from natural habitats in. Portaels, F., *et al.* .....(A) 408

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 50, Number 1, March 1982

Original Articles — **Page**

Mshana, Robert N., Belehu, Ayele, Stoner, Gerald L., Harboe, Morton, and Haregewoin, Abebe. Demonstration of Mycobacterial Antigens in Leprosy Tissues. ---- 1

Ridley, Marian J., Russell, Deborah F., and Ridley, Dennis S. An Immunoperoxidase Study of Immunological Factors in Skin Lesions Across the Spectrum of Leprosy. ---- 11

Seydel, Joachim Karl and Wempe, Ellen Gertrud. Bacterial Growth Kinetics of "*M. lufu*" in the Presence and Absence of Various Drugs Alone and in Combination. A Model for the Development of Combined Chemotherapy Against *M. leprae*? ---- 20

Duncan, M. Elizabeth and Pearson, John M. H. Neuritis in Pregnancy and Lactation. ---- 31

Warndorff-van Diepen, Titia. Smear Site Selection with Particular Reference to the Fingers. A Study in 244 Long-Treated Lepromatous Patients. ---- 39

Gupta, S. C., Chhabra, B., Mehrotra, T. N., and Bajaj, A. K. A Study of Antispermatozoal Antibodies in Leprosy. ---- 43

Wangel, Anders Gustaf, Wegelius, Otto, and Dyrting, Age Emil. A Family Study of Leprosy: Subcutaneous Amyloid Deposits and Humoral Immune Responses. ---- 47

Date, Anand, Mathai, Rachel, Pandey, A. P., and Shastry, J. C. M. Renal Transplantation in Leprosy. ---- 56

Barton, R. P. E., Rees, Richard J. W., McDougall, A. Colin, and Ellard, Gordon A. The Nose in Lepromatous Leprosy; Bacteriological and Histopathological Studies of Patients Treated with Dapsone Monotherapy for Varying Periods of Time. ---- 58

Fukunishi, Yukiko, Okada, Seitaro, Nishiura, Mitsugu, and Kohsaka, Kenji. Ultrastructural Features of the Multiplication of Human and Murine Leprosy Bacilli in Macrophages of Nude Mice. ---- 68

Binkhuysen, Fred and Das, Pranab Kumar. Ultrastructural Characteristics of *Mycobacterium bovis* BCG and *Mycobacterium leprae*. ---- 76

Dhople, Arvind M. and Storrs, Eleanor E. Adenosine Triphosphate Content of *Mycobacterium leprae*: Effect of Purification Procedures. ---- 83

Seydel, Ulrich, Lindner, Buko, Seydel, Joachim K., and Brandenburt, Klaus. Detection of Externally Induced Impairments in Single Bacterial Cells by Laser Microbe Mass Analysis. ---- 90

Shepard, Charles C. Statistical Analysis of Results Obtained by Two Methods for Testing Drug Activity Against *Mycobacterium leprae*. ---- 96

Editorials

The 1981 Journal—A Continuing Perspective. (Robert C. Hastings) ---- 102

Correspondence

Leprosy Eradication in the Developing Countries: The Required Necessary Foundation. (S. N. C. Wemambu) ---- 117

Name Changes Reflect Trends. (Prof. Abrahão Rotberg) ---- 117

News and Notes ---- 119

Book Reviews ---- 125

Current Literature ---- 126

Special Grantors and Sustaining Members ---- 137

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 50, Number 2, June 1982

Original Articles — **Page**

Warndorff-van Diepen, Titia. Clofazimine-Resistant Leprosy, a Case Report. ---- 139

Phadnis, Madan C., Mehta, M. C., Bharaswadker, M. S., Kolhatkar, M. K. and Bulakh, P. M. Study of Renal Changes in Leprosy. ---- 143

Kumar, Nirmal, Malhotra, Veena, Singh, Rattan, Vij, J. C. and Anand, B. S. Structure and Function of the Small Bowel in Lepromatous Leprosy. ---- 148

Murray, Katherine A. Syphilis in Patients with Hansen's Disease. ---- 152

Sharma, Vinoy K., Saha, Kunal and Sehgal, Virender N. Serum Immunoglobulins and Autoantibodies During and After Erythema Nodosum Leprosum (ENL). ---- 159

Turkel, Susan Beckwitt, Van Hale, Harriet McMurria and Rea, Thomas H. Ultrastructure of the Dermal Microvasculature in Leprosy. ---- 164

Liu Tze-Chun, Yen Li-Zung, Ye Gan-yun and Dung Gu-Jing. Histology of Indeterminate Leprosy. ---- 172

Job, Charles K., Kirchheimer Waldemar, F. and Sanchez, Rita M. Tissue Response to Lepromin, an Index of Susceptibility of the Armadillo to *M. leprae* Infection—A Preliminary Report. ---- 177

Kvach, James T. and Veras, Jose R. A Fluorescent Staining Procedure for Determining the Viability of Mycobacterial Cells. ---- 183

Nakamura, Masahiro. Stimulation of Growth of *Mycobacterium lepraemurium* in Cell-Free Liquid Medium by DL-Aspartic Acid. ---- 193

Camargo, Edwaldo E., Kertcher, Judith A., Larson, Steven M., Tepper, Byron S. and Wagner, Henry N., Jr. Radiometric Measurement of Differential Metabolism of Fatty Acid by Mycobacteria. ---- 200

Editorials

BCG Vaccination in Leprosy. (Janet E. Price) ---- 205

Obituary

Lara, Casimiro B. ---- 213

Correspondence

Co-incident (Simultaneous) Dapsone Sensitive and Dapsone Resistant Leprosy. (A. Colin McDougall and W. Felton Ross) ---- 214

Chemotaxis of Monocytes in Hanseniasis. (Rubem David Azulay) ---- 215

IgE in Leprosy. (Mario Nuti, Guido Rasi, Carla Rosa, Sergio Bonini) ---- 217

Salivary Immunoglobulins in Leprosy. (S. C. Gupta, B. Chhabra, T. N. Mehrotra, A. K. Bajaj, and S. N. Sinha) ---- 218

Serological Activity of Purified Glycolipid from *Mycobacterium leprae*. (Sheila N. Payne, Philip Draper, and R. J. W. Rees) ---- 220

Indeterminate Leprosy—A Valid Clinical Concept. (Stanley G. Browne) ---- 221

Reply to Dr. Browne's Letter to the Editor. (John H. S. Pettit) ---- 224

News and Notes ---- 225

Book Reviews ---- 239

Current Literature ---- 243

Special Grantors and Sustaining Members ---- 270

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 50, Number 3, September 1982

Original Articles — **Page**

Melsom, Reidar, Harboe, Morten, and Naafs, Ben. Class Specific Anti-*Mycobacterium leprae* Antibody Assay in Lepromatous Leprosy (BL-LL) Patients During the First Two to Four Years of DDS Treatment ... 271

Wallach, Daniel, Cottenot, François, and Bach, Marie-Anne. Imbalances in T Cell Subpopulations in Lepromatous Leprosy ... 282

Mshana, Robert N., Haregewoin, Abebe, Harboe, Morten, and Belehu, Ayele. Thymus Dependent Lymphocytes in Leprosy. I. T Lymphocyte Subpopulations Defined by Monoclonal Antibodies ... 291

Gupta, Sunil K., Bhutani, Lalit K., and Nath, Indira. The *In Situ* Characteristics of Mononuclear Cell Infiltrates in Dermal Lesions of Leprosy ... 297

Rojas-Espinosa, Oscar, Rodríguez-Paez, Lorena, González-Cruz, Ofelia, and Estrada-Parra, Sergio. Phagocytosis in Leprosy. 5. The Effect of the Infection with *Mycobacterium lepraemurium* on the Level of Diverse Hydrolytic Lysosomal Enzymes of Murine Peritoneal Macrophages ... 306

Liu Jihe, Shi Yuanfu, Kong Qingying, and Ye Gan-yun. Preliminary Observation on Langerhans' Cells in Leprosy ... 316

Khuller, Gopal K., Malik, Uma, and Kumar, Bhushan. Antibodies to Sulfolipids in Human Leprosy Sera ... 319

Sen, Dhan Krishna and Sarin, Guatam Sarup. Tear Lysozyme in Lepromatous Leprosy ... 322

Haddad, Nagib, Bechelli, Luiz Marino, Kwapinski, J. B. G., and Simão, Emília Tavares. Double Blind Trial on the Effect of Certain Soluble Cytoplasmic Mycobacterial Antigens on the Late Reactivity to Lepromin ... 325

Koticha, Kumudchandra K., Nair, P. R. Raveendran, and Juwatkar, Parsharam S. A Study of 922 Bacteriologically Positive Leprosy Cases ... 330

Worth, Robert M. and Bomgaars, Mona R. Immigration and Leprosy in Hawaii, 1960–1981 ... 335

Editorials

Significance of Antibody Studies in Leprosy and Experimental Models of the Disease. (Morten Harboe) ... 342

The Immunological Basis of Glomerular Disease in Leprosy—A Brief Review. (Anand Date) ... 351

Factors Influencing the Quality of Service to Leprosy Patients. (A. Colin McDougall) ... 355

Obituary

Karat, Aaron Benedict Abiel ... 359

Correspondence

***In Situ* Characterization of T Lymphocyte Subsets in Leprosy Granulomas.** (Robert L. Modlin, Florence M. Hofman, Clive R. Taylor, and Thomas H. Rea) ... 361

The Dissociation of Hypersensitivity and Immunity in the Spectrum of Leprosy. (D. S. Ridley) ... 363

Short-term, Multi-drug Chemotherapy of Leprosy and Type I Reaction. (Roy E. Pfaltzgraff) ... 365

The Immunopathology of Nerve Damage in Leprosy. (Robert N. Mshana, Colin L. Crawford, David P. Humber) ... 367

Cultivation, the Neglected Priority. (Laszlo Kato) ... 368

Isolation of Fastidiously Growing Mycobacteria from Armadillo Livers Infected with *Mycobacterium leprae*. (F. Portaels and S. R. Pattyn) ... 370

News and Notes ... 375

Book Reviews ... 383

Current Literature 385
Statement of Financial Condition 410
Special Grantors and Sustaining Members 413

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 50, Number 4, December 1982

Original Articles **Page**

Convit, Jacinto, Aranzazu, Nacarid, Ulrich, Marian, Pinardi, Maria E., Reyes, Oscar, and Alvarado, Jorge. Immunotherapy with a Mixture of *Mycobacterium leprae* and BCG in Different Forms of Leprosy and in Mitsuda-negative Contacts. 415

Duncan, M. Elizabeth, Pearson, John M. H., Ridley, Dennis S., Melsom, Reidar, and Bjune, Gunnar. Pregnancy and Leprosy: The Consequences of Alterations of Cell-mediated and Humoral Immunity During Pregnancy and Lactation. 425

Shield, Michael J., Stanford, John L., Garbajosa, Gallego, Draper, Philip, and Rees, Richard J. W. The Epidemiological Evaluation, in Burma, of the Skin Test Reagent LRA6; a Cell-free Extract from Armadillo-derived *Mycobacterium leprae*. Part 1: Leprosy Patients. 436

Shield, Michael J. and Stanford, John L. The Epidemological Evaluation, in Burma, of the Skin Test Reagent LRA6; a Cell-free Extract from Armadillo-derived *Mycobacterium leprae*. Part 2: Close Contacts and Non-contacts of Bacilliferous Leprosy Patients. 446

Reitan, Liv Jorun, Closs, Otto, and Belehu, Ayele. *In vitro* Lymphocyte Stimulation in Patients with Lepromatous and Borderline Tuberculoid Leprosy. The Effect of Dapsone Treatment on the Response to *Mycobacterium leprae* Antigens, Tuberculin Purified Protein Derivative and Non-mycobacterial Stimulants. 455

Sinha, Surendra, N., Gupta, Suresh C., Bajaj, Ashok K., Srivastava, Navin P., and Mehrotra, Triyugi N. Effect of Dapsone on Blood Lactic and Pyruvic Acids in Leprosy. 468

Liu Jihe, Kong Qingying, Ye Gan-yun, Xia Mingyu, Huang Li, and Zhu Wenyuan. Observations on Ultrastructure of Histoid Leproma. 471

Girdhar, B. K. and McDougall, A. Colin. The Morphology of Bacilli at Different Levels of the Dermal Infiltrate in Lepromatous Leprosy. 477

Nakamura, Masahiro, Matsuo, Yoshiyasu, Mori, Tatsuo, Okada, Seitaro, Nakayama, Tetsu, Saito, Hajime, Ito, Tonetaro, Koseki, Yuichi, Ogawa, Tatsuji, Ishihara, Shigenori, Kohsaka, Kenji, Nakamura, Kagunari, and Ishidate, Morizo. Failure to Validate the Growth of *Mycobacterium leprae* on M-Y 14b Agar Medium. 480

Job, Charles K., Kirchheimer, Waldemar F., and Sanchez, Rita M. Borderline Leprosy in an Experimentally Infected Armadillo. 488

Turcotte, Raymond and Lemieux, Suzanne. Lack of a Sustained Protection Against Murine Leprosy in C3H Mice Vaccinated with Extracts of *Mycobacterium lepraemurium* in Admixture with *Mycobacterium bovis* (BCG). 494

Editorial

Macrophages versus Lymphocytes in Leprosy. (Bernardo Beiguelman). ... 501

Obituary

Sagher, Felix. ... 508

Correspondence

Gilbert's Syndrome (Criggler-Najjar Type) with Hansen's Disease of the Dimorphous Type. (Kalyan Banerjee). ... 509

Primary Dapsone-resistant Leprosy in Republic of Korea. (Yoshiyasu Matsuo, Hiroshi Tatsukawa, Do-Il Kim, and Yong Ma Hah). ... 510

News and Notes ... 511

Book Reviews ... 524

Current Literature ... 534

U.S.-Japan Cooperative Medical Science Program, Seventeenth Joint Leprosy Research Conference, Sendai, Japan, 1982. ... 569

Reviewers ... 604

International Leprosy Association Organization and Membership, 1982. ... 605

Special Grantors and Sustaining Members. ... 617

Statement of Ownership, Management, and Circulation. ... 618

Index, Volume 50. ... 619